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CHAPTER 1: INTRODUCTION
1.1 Proteases as targets in breast cancer
According to the American Cancer Society statistics, breast cancer is the second leading
cause of cancer related deaths in women and it is estimated that 41,000 women will die from
breast cancer in 2017. Various types of breast cancers are defined by the cellular origin of the
malignancy, with the most common form of breast cancer being invasive ductal carcinoma
(IDC). IDC comprises approximately 80% of all breast cancers and arises from malignancy of
the breast ductal epithelium. For therapeutic reasons, IDC is divided into subtypes based on the
expression of cellular markers. These subtypes include estrogen/progesterone receptor positive
(ER/PR+), and HER2+ breast cancers. If breast tumors lack these markers then they are
classified as triple-negative breast cancers (TNBC), which comprises ~10-20% of breast
cancers in the United States (1).
Due to the lack of expression of hormonal markers and HER2, TNBC lack targeted
therapeutic options. Therefore, identification and validation of novel therapeutic targets in triplenegative breast cancer is needed. Dysregulated proteolysis is a hallmark of cancer, and
contributes to various events in cancer progression including angiogenesis, inflammation,
invasion, and cell survival (2). Pericellular and secreted proteases have garnered recent
attention due not only to their ability to degrade extracellular components to allow for invasion
into the surrounding stroma, but also for their ability to mediate signaling pathways through
processing of cytokines, growth factors, and adhesion molecules (3). During cancer progression
various environmental stimuli (e.g. hypoxia and acidification), and paracrine signaling between
tumor cells and stromal cells, induce the expression of proteases that promote tumor
development (2). Thus, identifying novel tumor promoting proteases is pivotal to our
understanding of the tumor/tumor-microenvironment interaction, and may translate into
candidate proteases for targeted therapy.

2
1.2 Major classes of human proteases
Proteolysis is a post-translational modification of proteins that is indispensable for
normal development and is carried out by a class of protein enzymes known as proteases.
Proteases are classified into subgroups based on their mechanism of catalysis and include:
serine, threonine, cysteine, aspartic, glutamic, and metallo- proteases. In total, the human
degradome (the entire set of known human proteases) consists of 569 proteases, with 34%
being metalloproteases, 31% serine, 26% cysteine, 5% threonine, and 4% aspartic proteases.
(4) Given the essential function of proteases, the regulation of both their expression and activity
is critical during normal physiological processes and perturbations in their expression and
activity is observed in many diseases, including cancer, making them attractive candidates in
drug discovery. (2)
1.2.1 Metalloproteases
The most well characterized metalloproteases in humans are members of the Metzincins
clan of metalloproteases, which include the matrix-metalloproteases (MMPs), the ‘a disintegrin
and metalloprotease’ [ADAMs], and meprin families (5,6). All metalloproteases are
characterized by the necessity for zinc ions to hydrolyze peptide bonds, thus the prefix of
“metallo”-protease. The MMPs, ADAMs, and meprin families of metalloproteases are
synthesized as zymogens, which functions as a control mechanism to prevent unintended
proteolysis (5). In humans there are a total of 24 MMPs, 22 ADAMs, and 2 meprin proteins
encoded within the human genome, giving rise to diverse functional roles (6,7).
In terms of drug discovery, MMP inhibitors were one of the first class of proteolytic
inhibitors to be tested in cancer patients. However, these protease inhibitors failed in clinical trial
settings as a result of severe side effects and little to no anti-tumor efficacy (8-10). A main
reason for the failure in clinical trials was due to the broad-spectrum inhibitor profile of these
drugs towards MMPs. The drugs used included marimastat, prinomastat, and hydroxamates
batimastat which have subsequently been shown to have a broad, rather than specific, inhibitory
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profile against MMP family members (8). Also contributing to the disappointing outcome of the
clinical trials was the lack of knowledge of the physiological roles and target substrates for this
family of proteases. Since the clinical trials, many studies have identified important roles of
these proteases in normal physiological cellular processes (8). The lessons learned from these
studies highlight the need to identify important biological features of proteases during drug
development, and the necessity for highly selective targeting of protease inhibitors to achieve
optimal anti-cancer effects while ensuring few and manageable side effects.
1.2.2 Cysteine proteases
The catalytic triad of cysteine proteases consists of Cysteine-Histidine-Asparagine
amino acid residues. The cysteine amino acid residue is responsible for the nucleophilic attack
on the reactive peptide bond of the target substrate. There are several well-known families of
cysteine proteases including cathepsins, caspases, and calpain protease families (11,12). The
family of caspase cysteine proteases were termed ‘C’-‘aspases’ with the C representing
cysteine of the cysteine protease family, and ‘aspase’ representing cleavage specificity after
aspartic amino acid residues of target substrates (13,14). Since their discovery, several
caspases have been found to play pivotal roles in mediating cell death through apoptosis (14).
These proapoptotic cysteine proteases are further classified as either initiator or executioner
caspases. Upon induction of apoptotic stimuli through either intrinsic or extrinsic pathways,
initiator caspases (caspases -8, -9, -10) are activated through an allosteric mechanism where
two inactive monomers form active dimer complexes. These activated initiator caspases then
activate effector caspases (caspase -3, -6, -7) directly through proteolytic cleavage, which
mediate the ‘execution’ phase of apoptosis resulting in cell death (15,16).
Cathepsins are another class of proteases which are composed of 11 different types of
cysteine proteases (16). Cathepsins are found primarily in lysosomal compartments and
function in protein turnover. In addition to protein turnover, several cathepsins have been found
to play other important roles in cellular processes, such as bone reabsorption, generation of
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peptides for MHC II molecules, and apoptosis (17,18). In cancer, the aberrant extracellular
localization of several cathepsin family members have been shown to cleave various
extracellular matrix proteins, including laminin and type IV collagen (18). Calpains are another
well studied class of cysteine proteases with several of these proteases requiring calcium for
their activation (19). Currently there are 14 known calpain family members which have been
implicated in roles including cell motility and apoptosis (19).
1.2.3 Serine proteases
Serine proteases represent one of the most abundant and diverse groups of proteases,
involved in functions relating to blood coagulation, digestion, development, fibrinolysis,
immunity, and apoptosis (20). Serine proteases mediate catalysis through a neutrophilic attack
by a serine residue towards carbonyl moiety of the substrates peptide bond. The other amino
acids typically involved in catalysis of serine proteases include histidine and aspartic residues,
which form a charge-relay system to mediate hydrolysis of peptide bonds. One of the most wellstudied families of serine protease are the S1A family of the PA clan of serine proteases,
comprised of trypsin, chymotrypsin, and thrombin protease subfamilies.
One of the most well characterized serine protease pathways is the coagulation cascade
(i.e. bleeding arrest). To prevent excessive blood loss upon endothelial vessel injury, the liver
produces fibrinogen which upon conversion to fibrin stabilizes platelet plugs as an initial barrier
for the damaged vessel wall. A critical regulatory mechanism to prevent aberrant fibrin strand
formation, is that fibrin is first synthesized as inactive fibrinogen that is present in its soluble
form at high concentration in the blood at 2-5 mG/mL (21), but is incapable of producing fibrin
strands before activation by proteolytic cleavage. Upon endothelial injury, fibrin is converted
from fibrinogen by the protease thrombin, and thrombin is converted from prothrombin through
the coagulation cascade (22). Several bleeding disorders are caused by mutations in individual
components of the serine protease coagulation cascade. The most common disorders are
Hemophilia; Hemophilia A is due to deficiency of factor VIII, and hemophilia B is due to
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deficiency of factor IX (23). Hemophilia can be efficiently treated by replacement therapy with
recombinant coagulation factors.
Another well studied serine proteolytic system, known as the fibrinolytic system,
prevents excessive clot formation. Upon tissue occlusion during clot formation, the serine
protease tissue-plasminogen activator (tPA) is released from the endothelium. tPA then
converts plasminogen into its active form known as plasmin. Plasmin is then responsible for the
breakdown of fibrin blood clots into fibrin degradation products (22). A rare congenital disease,
known as human plasminogen deficiency, occurs in patients who have a mutation in the
plasminogen gene. This results in loss of the ability to break down fibrin during clot formation
and often leads to inflammation in the conjunctiva of the eye due to fibrin build-up. Plasminogen
deficient mice also display the same defect, with lost ability to degrade fibrin, leading to
thrombosis. However the mice develop normally and are able to reproduce, highlighting the
specific role of plasminogen in the fibrinolytic system (24).
1.3 Membrane-anchored serine proteases
Many well studied proteases are either secreted, for example plasminogen, or reside
intracellularly, for example cathepsins and caspases. However, at the turn of the millennium as
a result of the human genome sequencing project, a new group of serine proteases emerged
that reside on the cell surface and are termed either Type-I, Type-II, or GPI-anchored serine
proteases (3). The largest membrane anchored serine protease family is the Type-II
transmembrane serine proteases (TTSP), and are attached to the cell membrane through a
single amino- terminal hydrophobic region that signals for membrane localization. Two other
membrane anchored serine proteases, testisin and prostasin, localize to the cell surface through
a

glycosyl-phosphatidylinositol

linkage

(GPI-anchored).

Tryptase-γ1,

also

known

as

transmembrane tryptase, is the only Type-I transmembrane serine protease that contains a
carboxy- terminal hydrophobic region that signals for membrane localization (25).
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Tryptase-γ1 is highly expressed in the mast cells of both humans and mice (26-28).
Mature mast cells often reside close to the host-environment interface and thus play an
important role in the first line of defense to environmental insult and pathogens. Once mature
mast cells are activated, degranulation occurs resulting in the release of bioactive granule
compounds that incite an inflammatory response (29). Thus, given the high expression of
tryptase-γ1 in mast cells suggests a role for it in host defense against pathogens and insults.
Tryptase-γ null mice display no outwardly phenotype, however under experimentally induced
chronic obstructive pulmonary disease (COPD), tryptase-γ1 null mice displayed reduced
pulmonary macrophages, decreased histopathology scores, and decreased fibrosis in their
small airways (30). Additionally, in experimentally induced colitis experiments via dextran
sodium sulfate exposure, tryptase-γ null mice had a more positive outcome compared to WT
mice, with reduced histopathology scores and increased weight retention (30).
The GPI-anchored transmembrane serine proteases prostasin and testisin have been
shown to play important roles in normal physiological development through characterization of
knockout mouse models. Global knockout of prostasin results in embryonic lethality due to
impaired placental labyrinth maturation, indicating an essential role of prostasin during
embryonic development (31). Additionally, genetically engineered mice that have specific
knockout of prostasin in the skin die within 60 hours after birth due to a severely impaired
epidermal barrier leading to rapid dehydration, indicating an additional essential function for
prostasin in epidermal barrier development (32). Testisin displays high expression in the testis
in both humans and mice, and testisin knockout mice display no overt outward phenotype
(33,34). However, testisin knockout mice to have impaired spermatozoa development, with
decreased viable sperm counts, reduced motility, and decreased fertilization abilities, indicating
that testisin plays an important role in sperm maturation (34).
The type-II transmembrane serine protease (TTSP) family is the largest group of
membrane-anchored serine proteases and consists of 17 structurally unique multi-domain
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serine proteases (26). This family of proteases is sub-classified into four groups based off the
phylogenetic analysis of the serine protease (SP) domain, and the protein domain structure
within the stem region. These subfamilies include the Matriptase, Hepsin/TMPRSS, HAT/DESC,
and Corin subfamilies (Fig. 1). Several members of the TTSP family have been intensely
studied and it has been demonstrated that some of these membrane-anchored serine proteases
regulate fundamental cellular and developmental processes, including tissue morphogenesis,
epithelial barrier function, ion and water transport, and cellular iron export (35) (discussed in
more detail in section 1.5).
1.4 Characteristic features of Type-II transmembrane serine proteases
TTSP’s are synthesized as “single-chain” inactive zymogens that require proteolytic
cleavage at conserved activation sites to generate “two-chain” active proteases. Upon
activation, the serine protease domain remains tethered to the stem-region through a di-sulfide
bond, thus remaining surface-associated. This feature of TTSPs functions as a mechanism to
control spatial and temporal proteolytic activity when appropriate. The physiologically relevant
proteases responsible for proteolytic activation of TTSP family members is not known for many
TTSPs, however several TTSP family members have been shown to be capable of autoactivation (36). The mechanism by which auto-activation occurs is unknown, however it likely
involves a homo-dimerization or oligomerization. (36)
Other post-translational modifications of TTSP family members include glycosylation and
phosphorylation. N-linked glycosylation of several TTSP family members has been shown to
play a critical role in their activation and localization. For example, N-linked glycosylation is
critical for both activation and ectodomain shedding of corin and matriptase-2. (37,38).
Additionally, glycosylation of matriptase is essential for matriptase auto-activation (39). The
intracellular domains of TTSPs vary in length from 20 to 160 amino acids, with Hepsin
containing the shortest, and TMPRSS13 containing the longest. (25) Several TTSP family
members contain putative consensus sequences for phosphorylation sites within the
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Figure 1: The membrane anchored serine proteases

Figure 1. Membrane anchored serine proteases. The 20 known membrane anchored
serine proteases. Tryptase-γ is the only known type-I transmembrane serine protease, and
contains a carboxy-terminal hydrophobic region and an N-terminal serine protease domain
(green oval). The two GPI-anchored serine proteases prostasin and testisin attach to the
membrane through a glycophosphatidylinositol (GPI) anchor. The stem regions of the type-II
transmembrane serine protease (TTSP) family members are composed of ow-density
lipoprotein receptor class A (LDLA); sea urchin sperm protein, enteropeptidase, and agrin
(SEA); Cls/Clr, urchin embryonic growth factor, and bone morphogenic protein-1 (CUB); meprin,
A5 antigen, and receptor protein phosphatase μ (MAM); frizzled; and group A scavenger
receptor. The four TTSP subfamilies are known as the HAT/DESC, hepsin/TMPRSS,
Matriptase, and corin subfamilies.
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intracellular domains, and TMPRSS13 was the first and currently only TTSP family member
identified to be modified by phosphorylation (discussed in detail in section 3.3) (40).
Unlike the Type-I and GPI-anchored membrane serine proteases, where the catalytic
domain lies adjacent to the cell surface, TTSP family members also contain several protein
domain structures within the stem region, with the SP domain localizing at the C-terminus
(extracellular side of the cell membrane) (See Fig. 1). These protein domain structures within
the stem region play important roles in binding interactions, activation, and inhibition (26). The
most common protein domain of TTSP family members is the low density lipoprotein receptor
class A domain (LDLRA). Additional domains include: Group A scavenger receptor (SR)
domains, frizzled domains, Cls/Clr, urchin embryonic growth factor and bone morphogenic
protein 1 (CUB) domains, sea urchin sperm protein, enterokinase, agrin (SEA) domains, and
meprin, A5 antigen, and receptor protein phosphatase µ (MAM) domains. Recently, it has been
suggested that SEA domain cleavage of matriptase is required for efficient transport to the cell
surface by inhibitor mediated stabilization by the endogenous TTSP inhibitor hepatocyte growth
factor activator inhibitor-2 (HAI-2), highlighting the unique regulatory role of these protein
domain structures in TTSP function (41).
1.4.1 Inhibition of TTSP proteolytic activity by endogenous inhibitors
As mentioned previously, TTSPs are synthesized as inactive zymogens that require
proteolytic cleavage to generate an active “two-chain” protease. To prevent unabated
proteolysis upon activation, TTSP family members are inhibited by the endogenous serine
protease inhibitors, HAI-1 and HAI-2 (42). HAI-1, -2 are kunitz domain type serine protease
inhibitors that both contain two kunitz domains (KD1 and KD2), however the KD1 domain of
HAI-1 is responsible for the proteolytic inhibition of matriptase (43), and thus may be the primary
kunitz domain to elicit inhibitory activity towards other TTSP family members. HAI-1 and HAI-2
are a competitive type of inhibitor that form a tight non-covalent complex with the SP domain.
These two inhibitors play essential roles in normal development, since genetic ablation of either
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HAI-1 or HAI-2 results in embryonic lethality due to defects in placental labyrinth development in
both HAI-1 and HAI-2 null mice, as well as neural tube closure in HAI-2-null mice (44-46). The
embryonic lethality upon loss of HAI-1 or HAI-2 is rescued upon concomitant genetic loss of
matriptase (46,47). These findings underscore the importance of precise regulation of
matriptase proteolytic activity during embryonic development.
A mutation in HAI-2 has been discovered in patients who suffer from a congenital
disease known as congenital sodium diarrhea (CSD). Patients who have this mutation suffer
from dehydration and diarrhea due to increased sodium levels in the intestinal tract (48).
Although the exact mechanism by which electrolyte and nutrient imbalance occurs is unknown,
it has been proposed that loss of inhibitory activity of HAI-2 towards matriptase results in
increased amounts of prostasin activation, which in turn activates the Epithelium sodium
channel (ENaC), causing aberrant sodium transport in these patients (49,50). An alternative
hypothesis has also recently been proposed, where loss of proteolytic inhibition of matriptase in
HAI-2 mutant patients results in increased matriptase mediated cleavage of EpCAM. This then
causes dysregulated tight-junction stabilization and formation, resulting in impaired paracellular
transport of ions (51).

Interestingly, a recent study examining the effects of this mutation in

vitro on TTSP family members observed a complete loss of proteolytic inhibition towards
TMPRSS13, as well as partial loss of inhibitory activity towards matriptase (52).
It has been demonstrated that dysregulated expression level ratios of TTSP’s and the
HAI-1, -2 inhibitors contributes in cancer progression, with decreased expression of inhibitors
relative to TTSP family members (53). List et al. demonstrated that transgenic expression of
matriptase in the epidermis results in the development of squamous cell carcinoma, however
double transgenic mice expressing matriptase with the inhibitor HAI-1 significantly reduced
tumor development in these mice (54). Therefore, this indicates that the matriptase:HAI-1
expression ratio may play a role in the development of cancer, and that inhibition of matriptase
proteolytic activity effectively abrogates matriptase mediated tumor development.
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In addition to functioning as important inhibitors towards TTSP proteolytic activity, HAI-1,
and -2 have garnered recent attention in their ability to stabilize and promote proper activation,
localization, and expression of TTSP’s. Therefore it is demonstrated that the HAI-1 and HAI-2
inhibitors interact with the inactive zymogen forms of TTSP family members, including
matriptase (39,41,43), hepsin (55), and TMPRSS13 (40), to facilitate their activation. HAI-1, -2
mediated transport of TMPRSS13 is discussed in more detail in chapter 3.
1.5 TTSP’s in normal development
Research of TTSP family members has revealed significant insight towards the
physiological roles of many TTSP family members. However, the in vivo substrates for many
TTSP family members remain unknown, thus limiting the knowledge of the precise mechanisms
by which TTSP’s promote normal development. Nevertheless, numerous knock-out mouse
studies have revealed that many of these family members play important roles in maintaining a
normal phenotype in vivo and for a subset of TTSPs the physiological substrates have been
identified and validated in mouse models and/or in humans harboring TTSP mutations. The
section below covers a select number of TTSP family members that have been implicated to
play important roles in normal human development through characterization of genetically
engineered mouse models.
1.5.1 Matriptase
Matriptase is one of the most well-studied TTSP family members to date, and is critically
involved in proper skin epidermal differentiation and development. Matriptase has a broad
expression profile in the epithelium of tissue, and is found at highest expression in the skin,
gastrointestinal tract, hair follicles, and kidney in adult tissue. Matriptase null mice suffer from
severe post-natal dehydration resulting in mortality due to defects in the epidermal skin barrier,
exemplifying the importance of matriptase in epidermal barrier development (56). Physiological
substrates for matriptase include the GPI-anchored serine protease, prostasin, which was
discovered by characterizing prostasin-null mice, which exhibit an identical phenotype to
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matriptase-null mice (32,57). Furthermore, it was demonstrated that the epidermis from
newborn matriptase null mice contained no detectable active two-chain prostasin in contrast to
control littermate mice where active prostasin was readily detected (57). Therefore, a
matriptase-prostasin proteolytic cascade has been hypothesized to be essential for proper
epidermal barrier development.
Mutations of matriptase have also been discovered in patients who suffer from a
congenital disease known as Autosomal Recessive Ichthyosis with Hypotrichosis (ARIH).
Patients who harbor matriptase mutations display abnormal epidermal differentiation and hair
abnormalities (58,59) and at the molecular level, these patients also have impaired profilligrin
processing, a key step in epidermal differentiation. Interestingly, these phenotypes are
mimicked in matriptase hypomorphic mice that have reduced matriptase proteolytic activity.
1.5.2 Hepsin
Hepsin is a member of the Hepsin/TMPRSS subfamily of TTSP family members and
was originally cloned from human liver cDNA libraries in 1988. Since its discovery it has been
implicated in roles including cochlear development and hepatic structural homeostasis. The first
study characterizing hepsin-null mice unexpectedly observed defects in normal hearing,
resulting from defective cochlear development (60). The mechanism by which hepsin regulates
proper cochlear development is unclear, however hepsin-null mice do display low levels of the
thyroid hormone thyroxine, which has previously been shown to be critical in cochlear
development. Therefore, it is suggested that the hearing defect in hepsin-null mice may be due
to defects in thyroid hormone metabolism. (60)
An in vivo substrate for hepsin has been identified in liver tissue. Hsu et al. characterized
the liver architecture of hepsin null mice and observed defects in hepatocyte architecture and
decreased activation of c-Met signaling in the liver (61). This phenotype was rescued when
hepsin null mice were treated with active recombinant HGF, thus suggesting the defects
observed were caused by insufficient hepsin-mediated pro-HGF processing. To test whether the
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livers of hepsin-null mice have defects in pro-HGF processing, lysates from livers of WT or
hepsin null mice were treated with pro-HGF to assess the ability of HGF processing in vitro.
Liver lysates from hepsin-null mice displayed impaired pro-HGF processing compared to WThepsin liver lysates (61). Therefore, hepsin plays an important role in maintaining proper liver
architecture through pro-HGF processing.
1.5.3 TMPRSS6
TMPRSS6, also known as matriptase-2, plays a vital role in iron homeostasis by
regulating hepcidin expression. The hepatic hormone hepcidin is a negative regulator of iron
export into the plasma since it is responsible for down-regulation of the iron exporter, ferroportin.
TMPRSS6 null mice display a marked up-regulation of hepcidin and a corresponding decrease
in expression of ferroportin, thus resulting in iron deficiency anemia (62). Patients with frameshift and missense mutations in the TMPRSS6 gene show a similar phenotype to TMPRSS6
null mice, resulting in iron deficiency anemia (63). TMPRSS6 has been shown to regulate
hepcidin expression by degradation of hemojuvelin, which is a co-factor of bone morphogenic
protein that regulates hepcidin expression (64).
1.5.4 TMPRSS13
TMPRSS13 deficient mice were first characterized by Madsen et al. in 2014 and
revealed that TMPRSS13 has a broad expression profile, with the strongest expression
occurring in the skin, tongue, lip, hard palate, cornea, and bladder (65). Madsen et al. also
observed that TMPRSS13 deficiency results in impaired epidermal skin barrier development as
measured by an increased rate of trans-epidermal fluid loss in TMPRSS13 deficient mice, and a
compacted stratum corneum. Interestingly however, the impaired epidermal barrier did not
seem to be caused by abnormal tight-junction formation. In contrast to matriptase null mice that
succumb to the severely compromised epidermal barrier function within 24-48 after birth (List et
al.), TMPRSS13 deficient mice display a much less severe phenotype and no lethality is seen.
At weaning age the mice are indistinguishable from control mice and no difference in overall
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adult health and life span is observed. (65). Currently the in vivo substrates for TMPRSS13 are
unknown, however TMPRSS13 can activate the oncogenic signaling molecule pro-HGF under
in vitro conditions (66).
1.6.0 TTSP’s in cancer progression
This research (section 1.6.0 thru 1.6.4) was originally published in the journal Biological
Chemistry. Murray AS, Varela FA, List K. Type II transmembrane serine proteases as potential
targets for cancer therapy. DOI: 10.1515/hsz-2016-0131.
Beyond the role that TTSPs play in normal physiological processes, TTSPs have also
been studied extensively in disease, including cancer, where their expression is often
dysregulated. Promotional or causal roles of several TTSPs have been demonstrated in vivo
using genetic engineering or administration of protease inhibitors to manipulate protease levels
and activity. As evidence continues to accumulate about their functional roles in cancer
development and progression, TTSPs represent exciting future therapeutic targets. This section
will focus on select TTSPs that to date have been most extensively studied in cancer.
1.6 Matriptase
This protease is one of the most extensively studied TTSPs with more than 300
published articles characterizing expression profiles, gene-regulation, structural biology,
regulation by endogenous inhibitors, identification of critical substrates, determination of
physiological and pathophysiological functions, and development of synthetic inhibitors and
imaging tools. Matriptase is upregulated in breast, cervical, colorectal prostate, endometrial,
esophageal squamous cell carcinoma, gastric, head and neck, and pancreatic carcinoma; and
in tumors of the lung, liver, and kidney among others (67-70). Increased matriptase expression
correlates with advanced clinicopathological stages in many of these cancers, and de novo
expression is found in ovarian and cervical carcinoma where expression levels also correlate
with histopathological grade (71-73).
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Matriptase activity is mainly regulated by the transmembrane serine protease inhibitors,
HAI-1 and HAI-2 in vivo (44,46,74,75). In expression studies, an imbalance between matriptase,
HAI-1 and HAI-2 exists in several cancer types including ovarian and colorectal cancer where
the matriptase/ HAI-1 ratio is increased and in prostate and endometrial carcinoma where
matriptase/HAI-2 ratios are increased (76-80).
The role of matriptase in vivo has also been studied in detail in breast cancer. In an
oncogene-induced mouse mammary carcinoma model, hypomorphic matriptase mice with
reduced levels of matriptase displayed a significant delay in tumor formation and blunted tumor
growth (81). The reduced tumor growth was associated with a profound decrease in cancer cell
proliferation. Mechanistic studies demonstrated that the proliferation deficiency was caused by
the impairment of carcinoma cells, in cell lines and in vivo, to initiate the activation of the c-Met
signaling pathway in response to fibroblast-secreted pro-hepatocyte growth factor (pro-HGF). In
primary mammary carcinoma cells and human breast cancer cell lines, addition of HAI-1 and
HAI-2 inhibited pro-HGF mediated c-Met signaling and cell proliferation (81). Importantly,
inhibition of matriptase catalytic activity using a selective small-molecule inhibitor efficiently
abrogates the activation of c-Met, Gab1 and AKT, in response to pro-HGF, which functionally
leads to attenuated cancer cell proliferation and invasion. The selective inhibitor of matriptase,
IN-1 used in the study contains a ketobenzothiazole serine trap and was designed based on the
auto-catalytic domain (RQAR) of matriptase (82). It still remains to be tested whether IN-1 is
suitable as an anti-tumor drug in vivo. Other inhibitors have been developed including MCoTI-II
(based on cyclic microproteins of the squash Momordica cochinchinensis trypsin-inhibitor
family) which inhibits the proteolytic activation of pro-HGF by matriptase but not by hepsin, in
both purified and cell-based system (83).
In prostate cancer, several matriptase inhibitors have been tested in xenograft models.
In an ectopic subcutaneous model, a small molecule inhibitor of matriptase, CVS-3983,
significantly suppressed the growth of human prostate cancer cell lines in nude mice (84). The
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authors propose that the effect was mainly caused by the abrogation of invasion since tumors
remained localized to the site of injection in treated mice and failed to invade the subscapular
area as compared to tumors in vehicle treated mice. Similarly, using matriptase inhibitors based
on bis-basic secondary amides of sulfonylated 3-amidinophenylalanine in an orthotopic
xenograft mouse model of prostate cancer resulted in reduced tumor growth, and tumor
dissemination (85). Together, these findings demonstrate that matriptase is critically involved in
cancer progression and lay the groundwork for future studies developing and testing smallmolecule matriptase inhibitors and their potential as novel targeted therapeutic drugs in cancer.
1.6.2 Hepsin
Hepsin/TMPRSS1

was

the first

serine

protease

characterized

to

contain

a

transmembrane domain, and was named based on its original identification in hepatocytes (86).
Hepsin is also expressed in kidney, pancreas, stomach, prostate and thyroid (87,88). Studies of
knockout mouse models of hepsin have demonstrated that this protease plays an important role
in cochlear development, is involved in regulating levels of the thyroid secreted hormone,
thyroxine, and is responsible for pro-HGF activation in the liver (60) (89) (61).
Many cancers display increased expression levels of hepsin including cancer of the
prostate, breast (90), ovary (91), kidney (92), and endometrium (93). Several studies have
revealed that hepsin is critically involved in prostate cancer progression. Klezovitch and
colleagues used transgenic mice to show that the overexpression of hepsin, under the control of
the probasin (PB) promotor, leads to a disorganized basement membrane and promotes
prostate cancer metastasis to the liver, bone and lungs when crossed to the LPB-Tag prostate
cancer model (94).
The Wnt/β-Catenin signaling pathway has been shown to play an important role in
prostate cancer progression. Dysregulation of this pathway by prostate-specific deletion of the
adenomatous polyposis coli (Apc) gene results in high-grade prostatic intraepithelial neoplasia
(PIN) lesions with rare occurrences of microinvasive characteristics in mice (95,96). Crossing
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PB-Hepsin mice to the prostate-specific Apc-deletion model (APCPBKO) to generate PBHepsin/APCPBKO mice results in progression from high-grade PIN lesions to large invasive
adenocarcinomas (95). Prostate tumors from PB-Hepsin/APCPBKO mice are hyperproliferative,
and contained significant numbers of apoptotic cells (95).
In an orthotopic xenograft model of prostate cancer, LnCaP cells were stably transfected
to overexpress hepsin (LnCaP-34) and injected into the anterior lobe of the prostate. Increased
final tumor weights were observed in mice injected with LnCaP-34 cells compared to LnCaP
cells expressing endogenous levels of hepsin (LnCaP-17 cells) (97). Additionally, metastatic
lesions to the periaortic lymph nodes were observed in mice injected with LnCaP-34 cells and
not found in mice injected with LnCaP-17 cells (97). To determine whether inhibition of hepsin
decreases the tumor growth in vivo, mice injected with LnCaP-34 cells were treated with a
PEGylated form of Kunitz domain-1, a potent hepsin active site inhibitor derived from HAI-1.
Treatment of established orthotopic LnCaP-34 xenografts tumors with PEGylated Kunitz
domain-1 significantly decreased contralateral prostate invasion and lymph node metastasis
(97).
In addition to prostate cancer, hepsin has been shown to have increased expression in
breast cancer (90). To determine whether hepsin promotes tumor progression in breast cancer,
Tervonen et al. performed grafting studies using primary mouse mammary epithelial cells from
transgenic mice harboring a Whey acidic protein (Wap) promoter-controlled c-Myc transgene.
The primary cells, that also expressed doxycyclin-inducible hepsin, were transplanted into
cleared fat pads of syngeneic wild-type virgin hosts. Chronic doxycyclin-induced expression of
hepsin resulted in decreased tumor latency in these mice, thus indicating a promotional role for
hepsin in breast cancer progression (98). Interestingly, hepsin acutely downregulated its
cognate inhibitor, HAI-1, in human MCF10A immortalized mammary epithelial cells, thereby
further increasing the hepsin/HAI-1 ratio. Furthermore, hepsin induced cellular changes in
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MCF10A cells commonly associated with invasive phenotypes and endowed cells with a strong
capacity to proteolytically activate pro-HGF, leading to activation of the c-Met receptor.
1.6.3 TMPRSS2
TMPRSS2 and TMPRSS4 are two other members of the TMPRSS/Hepsin subfamily of
TTSPs and remain relatively uncharacterized. Like many other TTSPs, expression of TMPRSS2
is localized to several types of epithelial tissues, including in the colon, small intestine, lung,
kidney, pancreas, and most notably in the prostate (99), where expression is highest. Both the
physiological function and substrates of TMPRSS2 have yet to be identified; therefore, much of
what is known about TMPRSS2 originates from its association with cancer. TMPRSS2 has long
been associated with prostate cancer following the identification of the oncogenic gene fusion
product with erythroblast transformation specific (ETS) transcription factors, such as ETSrelated gene (ERG) (100,101). Despite this, the role of the native TMPRSS2 protein and its
proteolytic activity in cancer is vastly understudied. In normal prostate epithelia, TMPRSS2
expression is localized to the cell membrane, however, mislocalization to the cytoplasm in
prostate cancer has been observed (102). In addition, both primary and metastatic prostate
tumors from patients display increases in TMPRSS2 levels, with increasing expression
correlating with elevated Gleason score, suggesting that TMPRSS2 may play a pro-oncogenic
and pro-metastatic role (102). Knockdown studies in human LNCaP prostate cancer cells
demonstrated that reduction of TMPRSS2 expression in cancer cells decreased cellular
invasion, tumor size, and incidence of metastases following xenografting in mice (103).
Interestingly, loss of TMPRSS2 expression does not impact cellular proliferation of LnCaP cells
in culture (103). However, a role of the tumor micro-environment is not taken into consideration
in mono-culture, therefore, a role for TMPRSS2 for cancer cell proliferation cannot conclusively
be excluded. It is worth noting that in a similar study, shRNA-mediated silencing of TMPRSS2 in
LNCaP-derived, bone metastatic castration-resistant (LNCaP C4-2B) cells led to a significant
reduction in cell proliferation and cell invasion compared with scrambled shRNA controls (104).
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In a study employing mice with a targeted deletion of the Tmprss2 gene, it was
demonstrated that the protease regulates cancer cell invasion and metastasis to distant organs
in the TRansgenic Adenocarcinoma Mouse Prostate (TRAMP) model of prostate carcinogenesis
(104). TRAMP tumors in Tmprss2−/− mice were significantly larger than those in control mice,
however, the incidence of metastasis to distant solid organs was substantially lower in the
TRAMP tumors arising in the Tmprss2−/− background. It was demonstrated that TMPRSS2
activated signaling incompetent pro-HGF to active HGF in vitro and it is hypothesized that
TMPRSS2-activated HGF consistently promotes invasion and metastasis, but differentially
enhances or suppresses proliferation. Importantly, a TMPRSS2 chemical inhibitor (bromhexine
hydrochloride) suppressed distant metastasis to lung and liver sites in TRAMP mice (104).
These links to prostate malignancy makes TMPRSS2 a promising target for drug
therapies. Of notable interest is that no phenotype affecting normal development or
physiological function has been observed in TMPRSS2 deficient mice. This suggests that
targeted ablation of TMPRSS2 in cancer may have minimal side effects (105). Upstream,
TMPRSS2 expression in prostate has been shown to be driven by androgen receptor signaling;
one notable consequence of this is the pro-oncogenic TMPRSS2-ERG fusion protein. This link
between androgen receptor signaling and TMPRSS2 has further pushed interest in androgen
receptor inhibitors as possible targets for inhibiting prostate cancer growth and metastasis. The
pro-oncogenic potential of TMPRSS2 has, as mentioned above, been linked to its activity,
specifically pertaining to its role in activating the HGF/cMET pathway (104). More recently, work
has uncovered matriptase as a possible substrate for TMPRSS2. A recent study found that
levels of active matriptase are increased in prostate cancer without increases in matriptase
transcript levels (103). Furthermore, orthotopic grafts of LNCaP cells over-expressing
TMPRSS2 exhibited increased levels of active matriptase, as well as increased metastases,
when compared to grafts expressing a control vector or catalytically dead TMPRSS2 (103).
Proteolytic homeostasis is important for maintaining normal tissue function, and increases in
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TMPRSS2 expression may shift the balance between matriptase activity and cognate inhibitors.
Additionally, beyond the HGF pathway, TMPRSS2 has been shown to activate proteaseactivated receptor 2 (PAR-2) in LNCaP cells (106), inciting another pathway which may be
involved in promoting metastasis (107). In addition to the TMPRSS2 inhibitor bromhexine
hydrochloride mentioned above, other synthetic inhibitors based on substrate analogs have
been developed and demonstrated to inhibit TMPRSS2 activity, as measured by cleavage of
influenza hemagglutinin (HA) (108). TMPRSS2 in airway epithelia is important for influenza
infection, and inhibition of TMPRSS2 with small molecule antagonists can prevent influenza
infection (109). However, these small molecule inhibitors also have strong affinities for other
proteases, such as matriptase, making the precise therapeutic mechanism by which these
molecules function unclear.
1.6.4 TMPRSS4
The physiological role of TMPRSS4 is currently not known, however, a mutation in this
gene has been associated with autosomal recessive cerebral atrophy (ARCA) (110). TMPRSS4
has been demonstrated to be upregulated in pancreatic, colorectal, thyroid, lung, and several
other cancers (111-114). Because of this broad expression profile in cancer, TMPRSS4 has
been a focal point of anti-cancer research in recent years. TMPRSS4 has been shown to
promote proliferative processes in lung and thyroid cancer cells, while shRNA targeting of
TMPRSS4 transcripts causes reductions in proliferation (115-117). Work using cultured lung
cancer cells demonstrated that TMPRSS4 promotes a mesenchymal and invasive phenotype,
suggesting a role for epithelial to mesenchymal transition (EMT) (117). Interestingly, increases
in markers for cancer stem cells (CSCs) such as aldehyde dehydrogenase (ALDH) and
octamer-binding transcription factor 4 (OCT-4) are strongly positively correlated with TMPRSS4
expression (118). Several reports have suggested that TMPRSS4 associates with poor
prognosis and survival in a variety of different cancers (117,119-122), which may be a result of
an increase in the CSCs population, although the factors leading to TMPRSS4 upregulation are
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still not identified. One recent finding suggests that increased TMPRSS4 in cancer may result
from gene-silencing of tissue factor pathway inhibitor 2 (TFPI-2), a consequence of improper
methylation (116). However, the mechanism which connects TFPI-2 and TMPRSS4 expression
remains unknown.
While the physiological substrates for TMPRSS4 are not yet fully elucidated, targeting
the activity of this protease may have benefits in the treatment of several types of cancer. With
several studies reporting reduced invasive and proliferative potential in lung and thyroid cells
following silencing of TMRSS4 expression (114,115), inhibitors of TMPRSS4 may provide an
edge in cancer treatment. Also, overexpression of TMPRSS4 in cell culture causes cancer cells
to be more resistant to several chemotherapeutics (118). A few small molecule inhibitors
derived from 2-hydroxydairylamide have been developed with inhibitory effects on the
proteolytic activity of TMPRSS4, with the consequence of impacting cancer cell invasiveness in
colorectal SW480 cancer cells (123). Given that TMPRSS4 impacts signaling pathways such as
cyclic AMP response element-binding protein (CREB)-cyclin D1 (115), inhibition of TMPRSS4
could impact many downstream processes important for a variety pro-oncogenic processes.
In conclusion, several TTSPs are candidate targets for cancer therapy and further
investigations are needed to identify whether other novel TTSP family members promote
tumor progression, thus validating them as potential therapeutic targets.
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CHAPTER 2: THE ROLE OF TMPRSS13 IN BREAST CANCER:
BACKGROUND AND SPECIFIC AIMS
2.1 Identification of novel TTSP’s in breast cancer
To identify novel TTSP family members that promote breast cancer progression, we
performed a systematic in silico screening of TTSPs in human and murine breast cancers using
the Oncomine™ microarray database. In silico analysis revealed a significant increase in the
overall TMPRSS13 transcript levels in human invasive ductal carcinoma (IDC) patient samples
compared to normal breast tissue (Fig. 13A). This finding was validated experimentally by
Western blot (WB) and immunohistochemistry (IHC) analyses, where higher expression of
TMPRSS13 was observed in human invasive ductal carcinoma patient samples and human
breast cancer cell lines compared to non-malignant breast tissue and cell lines, respectively
(Fig. 13).
TMPRSS13 is a relatively uncharacterized TTSP family member and little is known
about its basic biochemical features. TMPRSS13, also known as mosaic serine protease largeform (MSPL), belongs to the hepsin/transmembrane protease, serine (TMPRSS) subfamily.
TMPRSS13 contains an N-terminal intracellular domain, a transmembrane domain, a stem
region, and a C-terminal serine protease domain (5,6). The protease was originally cloned from
a human lung cDNA library and transcripts were detected in lung, placenta, pancreas, and
prostate (5). Subsequent studies revealed a broad TMPRSS13 protein expression profile in
epithelial tissue including epidermis, oral cavity, esophagus, bladder, stomach, small intestine,
thymus, kidney, and cornea (7). A physiological role for TMPRSS13 in epidermal barrier
development has been demonstrated in TMPRSS13-deficient mice, which display improper
formation of the cornified layer of the epidermis (7). Furthermore, TMPRSS13 has been
implicated in viral infection, since it proteolytically cleaves the viral hemagglutinin (HA) protein,
thereby enabling membrane fusion of highly pathogenic avian influenza viruses and
coronaviruses (8-10).
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Deficiency in knowledge of important biochemical features of TMPRSS13, including
activation and localization patterns, prompted an investigation to elucidate critical features of
TMPRSS13 to better understand its potential biochemical mechanisms of action. Additionally,
studies to identify whether increased expression of TMPRSS13 in breast cancer plays a causal
or promotional role were performed to identify whether TMPRSS13 represents a potential new
therapeutic target in breast cancer.

Hypothesis: TMPRSS13 expression is increased as

normal cells undergo neoplastic transformation, and is critically involved in breast cancer
progression and metastasis.
2.2 Specific Aims:
AIM 1) Biochemical characterization of proteolytic features of TMPRSS13
The activation, localization, regulation by inhibitors, and post-translational modifications
of TTSP family members play an important role in determining the physiological function of
these proteases in both normal physiological conditions and disease. These important features
are currently unknown for TMPRSS13 and were examined to better understand the functional
role of TMPRSS13 in breast cancer.
AIM 2) Expression profiling and functional analysis of TMPRSS13 in breast cancer
progression.
Expression of TMPRSS13 in breast cancer: The expression profile of TMPRSS13 was
assessed by in silico analysis followed by IHC and Western blotting to determine whether
TMPRSS13 there is differential expression of TMPRSS13 in breast cancer. Expression of
murine TMPRSS13 in the mammary cancer genetic model, MMTV-PymT, was also be
assessed,
Functional analysis upon loss of TMPRSS13 expression in breast cancer
In vivo: The TMPRSS13 loss-of-function (null) genetic mouse models will be
intercrossed with the MMTV-PymT transgenic breast cancer model to determine
effects on tumor onset, primary tumor growth, and metastasis to the lungs.
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AIM 3) The role of TMPRSS13 in pro-oncogenic cellular processes.
TMPRSS13-dependent proliferation, apoptosis, invasion, and chemosensitivity: Due to the lack
of targeted therapeutic options, we will determine whether TMPRSS13 functions in a protective
role to enhance tumor cell survival. The effects of RNAi-mediated silencing of TMPRSS13 will
be examined to determine whether loss of TMPRSS13 affects breast cancer cell proliferation,
cell death, and invasive capability. We will determine if TMPRSSS13 loss enhances
chemosensitivity in triple-negative breast cancer cells.
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CHAPTER 3: BIOCHEMICAL CHARACTERIZATION OF
TMPRSS13
This research (Chapter 3) was originally published in the Journal of Biological Chemistry.
Murray AS, Varela FA, Hyland TE, Schoenbeck AJ, White JM, Tanabe LM, Todi SV, List K.
Phosphorylation of the type II transmembrane serine protease, TMPRSS13 in Hepatocyte
Growth Factor Activator Inhibitor-1 and 2-mediated cell surface localization. J. Biol. Chem.
2017; 292:14867-14884. © the American Society for Biochemistry and Molecular Biology.
3.1 Materials and Methods
3.1.1 Cloning of full-length TMPRSS13 plasmid constructs
The human TMPRSS13 plasmid construct was obtained from GeneCopia with
Accession: BC114928.1 (Rockville, MD). The full-length human TMPRSS13 was PCR amplified
using a high-fidelity Platinum®Taq polymerase (Invitrogen, Life Technologies, Grand Island,
NY) with the following primers: 5’-GCCACCATGGAGAGGGACAGCCACGGG-3’ and 5’GGATTTTCTGAATCGCACCTCGCTCTC-3’. The resulting PCR fragment was cloned into the
pcDNA 3.1/V5-His TOPO® TA (Invitrogen, Life Technologies, Grand Island, NY) in frame with a
C-terminal His-tag and V5 epitope using standard TA cloning techniques. Point mutations for
S506A-TMPRSS13 and R320Q-TMPRSS13 were generated using a QuikChange II SiteDirected Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) following the manufacturers
protocol.

Primers

used

for

AAGAGGCCCCCCGGCGTCTCCCTGGCAG

S506A

mutagenesis
–

3’

5’

were:
and

5’

–
–

CTGCCAGGGAGACGCCGGGGGGCCTCTT – 3’. Primers used for R320Q mutagenesis were:
5’

–

CCATGACCGGGCAGATCGTGGGAGG

–

3’

and

5’

–

CCTCCCACGATCTGCCCGGTCATGG – 3’. Primers used for K151R mutagenesis were: 5’ CGCCAGGTGAACCTGGGCAGGCTC G – 3’ and 5’ - CGAGCCTGCCCAGGTTCACCTGGCG
– 3’. Primers used for K159R mutagenesis were 5’ - GGTAGCTGCCTCTGGCCCTCCCGCC –
3’ and 5’ - GGCGGGAGGGCCAGAGGCAGCTACC – 3’
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Untagged TMPRSS13 constructs were generated by PCR amplification of WT, S506A,
and R320Q expression vectors using the Platinum®Taq polymerase. The primers used for PCR
amplification were 5’ – AACCGGATCCATGGAGAGGGACAGCCACGGGAAT – 3’ and 5’ –
AACCCTCGAGTTAGGATTTTCTGAATCGCAC – 3’ which resulted in the PCR amplified
product encoding the native stop codon.

PCR amplified products and empty vector pcDNA

3.1/V5-His TOPO® TA were digested using the BamHI and XhoI restriction enzymes and
ligated using the T4 DNA Ligase (New England Biolabs, Ipswich, MA) following the
manufacturers protocol. N-terminal HA-tagged constructs were generated by PCR amplification
of untagged WT- and S506A-TMPRSS13 from of the pcDNA3.1 V5/His TOPO® expression
vectors. The plasmid containing the N-terminal HA tag was a kind gift from Dr. Todi and is
encoded in the pcDNA3.1-HA vector. PCR amplified products and the pcDNA3.1-HA plasmid
were digested using BamHI and XhoI restriction enzymes. Digested products were ligated with
the T4 DNA Ligase (New England Biolabs, Ipswich, MA) following the manufacturers protocol.
Transformation of all vectors was performed in TOP-10 competent cells (Invitrogen, Life
Technologies, Grand Island, NY) and positive clones were isolated and amplified using standard
techniques.
3.1.2 Transient transfections and Western blots
Transfection of HEK293T (ATCC, Manassas, VA) was performed using Lipofectamine®
LTX according to the manufacturer’s instructions (Invitrogen, Life Technologies, Grand Island,
NY).

HEK293T cells were cultured in Dulbecco’s modified Eagle’s media (DMEM) (Gibco, Life

Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum (Atlanta
Biologicals, Lawrenceville, GA). Transfection was performed with 1 µg plasmid DNA for single
transfections or 2 µg total plasmid DNA for co-transfections. Vectors included in transfections
were pcDNA3.1-TMPRSS13 vectors, empty vector pcDNA3.1, pcDNA3.1-HAI-1, pcDNA3.1HAI-2, or pEYFP-N1-HAI-2. The HAI vectors were kindly provided by Dr. Stine Friis, University
of Copenhagen. To analyze samples by Western blotting using the polyclonal anti-TMPRSS13
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antibody (α-extra-TMPRSS13)(PA5-30935 – Thermo Fisher Scientific, Life Technologies, Grand
Island, NY), twenty-four hours post transfection cells were washed 3x with PBS and serum free
DMEM was added for six hours when analyzing cell lysates and conditioned media from cells
expressing untagged TMPRSS13 constructs. Cells were then washed again 3x with PBS after
six hours and 1 ml of serum free media was added. Twenty-four hours after addition of serum
free media, conditioned media and lysates were collected. Cells were lysed using RIPA buffer:
50 mM, Tris, 150 mM, NaCl, 0.1% SDS, 0.5% deoxycholic-acid, 1% NP-40, pH 7.4
supplemented with protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) and cleared by
centrifugation at 12,000 x g at 4ºC. Protein concentrations were determined using a Pierce BCA
Protein Assay Kit (Thermo Scientific, Waltham, MA). For stringent lysis condition, SDS lysis
buffer (50 mM Tris-HCl pH 6.8, .25% Bromophenol Blue, 5% glycerol 1.5% SDS, and 100 mM
DTT) was boiled for 10 mins. Cells were washed 1x with PBS and then boiling stringent lysis
buffer was added to cells. Cells were scraped and collected and boiled for 10 minutes. After
boiling, cell lysates were centrifuged at 16,000 x g for 10 minutes at room temperature. Samples
were then boiled again for 5 minutes and 15 µl of each sample was loaded onto 10% SDS gels.
Protein samples were separated by SDS-PAGE using 10% Mini-PROTEAN® TGX Precast gels
(Bio-Rad Laboratories Hercules, CA) under reducing conditions and analyzed by Western
blotting. Primary antibodies used in Western blotting were polyclonal rabbit anti-TMPRSS13
raised against a recombinant protein fragment corresponding to a region within amino acids 195
and 562 of Human TMPRSS13 (anti-extra-TMPRSS13) (PA5-30935 – Thermo Fisher Scientific,
Life Technologies, Grand Island, NY), rabbit anti TMPRSS13 intracellular domain antibody (antiintra-TMPRSS13) raised against an epitope within the first (N-terminal) 60 amino acids
(ab59862 – Abcam, Cambridge, MA), V5 mouse monoclonal antibody (R96025 - Thermo Fisher
Scientific, Life Technologies, Grand Island, NY), HA rabbit polyclonal antibody (NB600-363 Novus Biologicals, Littleton CO), rabbit anti Phospho-(Ser/Thr) Phe antibody (#9631 - Cell
Signaling Technology, Danvers, MA) goat anti-HAI-1 (AF1048 - R&D Systems Inc., Minneapolis,
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MN), or goat anti-HAI-2 (AF1106 - R&D Systems Inc., Minneapolis, MN). Secondary antibodies
included goat anti-rabbit, goat anti-mouse (Millipore, Billerica, MA), and rabbit anti-goat (Dako,
Carpinteria, CA) HRP-conjugated antibodies.
3.1.3 Cloning and expression of the TMPRSS13 active serine protease domain in Pichia
pastoris
The human TMPRSS13 active serine protease domain was produced in yeast using a
Pichia Expression Kit (Invitrogen, Life Technologies, Grand Island, NY). Human TMPRSS13
serine protease domain was amplified and cloned into the pPIC9 vector at the XhoI and NotI
sites, using the primers 5’-TCTCTCGAGAAAAGAATCGTGGGAGGGGCGCTGGCCTCG -3’
and 5’-ATTCGCGGCCGCTTAGGATTTTCTGAATCGCAC -3’. Cloning resulted in TMPRSS13
serine protease domain sequence (Ile-Val-Gly) being inserted immediately following a Leu-GluLys-Arg KEX2 cleavage site encoded by the vector. The Leu-Glu-Lys-Arg-Ile-Val-Gly is cleaved
between Arg and Ile by the yeast protease KEX2 which is a transmembrane protease located in
the Golgi, rendering a secreted activated TMPRSS13 serine protease domain. The Pichia
pastoris secreted active TMPRSS13 SP-domain contains the same domain IVG N-terminus as
the mammalian active SP-domain. Transformation was performed in TOP-10 competent cells
(Invitrogen, Life Technologies, Grand Island, NY) and pPIC9-TMPRSS13 positive clones were
isolated and amplified using standard techniques. For transformation of Pichia pastoris, 20 µg of
pPIC9-human-TMPRSS13 or pPIC9 empty vector was digested with SalI, and purified by
phenol-chloroform extraction. Electroporation of linearized plasmid into the GS115 yeast strain
(Invitrogen, Life Technologies, Grand Island, NY) was performed at 1.5 kV using 0.2 cm
cuvettes (BioRad, Hercules, CA) in a BTX-Transporator Plus (Harvard Apparatus, Holliston,
MA). The expression of recombinant proteases in the conditioned media from individual yeast
clones was analyzed by SDS-PAGE and Western blotting using anti-extra-TMPRSS13 (PA530935 – Thermo Fisher Scientific, Life Technologies, Grand Island, NY)
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3.1.4 Chromogenic Proteinase Assays
The assays were performed in 96-well plates in a total reaction volume of 100 µl using
50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.01% Tween-20, 0.01% BSA for dilution of all samples.
5 nM of active recombinant TMPRSS13, matriptase, or empty vector control media was
incubated at 37 °C for 60 min with 100 μM of the synthetic peptide L-1720 Suc-Ala-Ala-Pro-ArgpNA (Bachem, Bubendorf, Switzerland) in the absence or the presence (inhibitor and substrate
added concomitantly) of recombinant soluble HAI-1 (60 nM) (R&D, Minneapolis, MN), HAI-2 (40
nM) (R&D, Minneapolis, MN), aprotinin (2 μM), leupeptin (20 μM), or benzamidine (2 mM)
(Thermo Scientific, Waltham, MA). Changes in absorbance at 405 nm were monitored using a
Magellan NanoQuant Infinite M200 Pro plate reader (Tecan US, Inc., Morrisville, NC).

For

measurement of chromogenic activity in cell extracts, samples were prepared and analyzed
according to (124).
3.1.5 Deglycosylation of TMPRSS13
Proteins in lysates or conditioned media prepared as indicated above were
deglycosylated using the PNGase F deglycosylation kit according to the manufacturer’s
instructions (New England Biolabs, Ipswich, MA).
3.1.6 Dephosphorylation of TMPRSS13 in lysates
For CIP treatment, 5 µg of protein lysates was added to 1x CutSmart® Buffer (New
England Biolabs, Ipswich, MA) for a total volume of 50 µl and treated with, or without, Alkaline
Phosphatase, Calf Intestinal (CIP) (New England Biolabs, Ipswich, MA). Lysates were incubated
at 37ºC for 60 minutes. After 60 minutes, Laemmli Sample Buffer with 5% 2-Mercaptoethanol
was added to the reaction and samples were boiled prior to Western blot analysis. For
dephosphorylation of MCF-7 lysates, 40 µg of protein was incubated in 1X NE Buffer for
Protein Metallo Phosphatases, 1mM MnCl2, and ddH2O for a total reaction volume of 50 µl, then
800 units of Lambda Protein Phosphatase (New England Biolabs, Ipswich, MA) or vehicle was
added to the sample. Reactions were incubated for 30 minutes at 30ºC. After 30 minutes,
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Laemmli Sample Buffer with 5% 2-Mercaptoethanol was added to the reaction and samples
were boiled prior to SDS-PAGE and Western blot analysis.
3.1.7 Knockdown of TMPRSS13 expression in cancer cells
MCF-7,

BT20,

and

HCC1937

breast

carcinoma

cells

and

DLD1

colorectal

adenocarcinoma cell line were purchased from ATCC (Manassas, VA). MCF-7 cells were
cultured in Dulbecco’s modified Eagle’s media (DMEM) (Gibco, Life Technologies, Grand
Island, NY) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA).
BT-20 cells were grown in Eagles + NEAA media (Eagle’s MEM with 2mM L-glutamine and
Earle’s BSS adjusted to contain 1.5 g/l sodium bicarbonate, 0.1 mM non-essential amino acids,
1 mM sodium pyruvate, and 10% FBS), HCC 1937 cells were grown in RPMI + L-GLUT media
(RPMI-1640 media with 2 mM L-glutamine adjusted to contain 1.5 g/l sodium bicarbonate, 4.5
g/l glucose, 10 mM HEPES, 1 mM sodium pyruvate, and 10% FBS), DLD1 cells were grown in
RPMI + L-GLUT media adjusted to contain 10% FBS. Transient knockdown of TMPRSS13
expression was performed using Lipofectamine® RNAiMAX according to the manufacturer’s
instructions (Invitrogen, Life Technologies, Grand Island, NY). Stealth siRNATM constructs were
obtained from Invitrogen life technologies (HSS130533 [corresponding to 33 in figure 5C], and
HSS130531 [corresponding to 31 in figure 5C). To detect endogenous TMPRSS13 species by
Western blotting, the polyclonal rabbit anti TMPRSS13 intracellular domain antibody was used
(ab59862 – Abcam, Cambridge, MA)
3.1.8 α2-Macroglobulin capture assay
30 µl of conditioned media from cells expressing WT-TMPRSS13 were added to 30 µl
buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, and 2.5 mM CaCl2) and treated with or without 30
nM α2-Macroglobulin (Calbiochem, San Diego, CA). Samples were incubated at room
temperature for 1 hour. Additionally, α2-macrogloublin was incubated with buffer alone as
control. Samples were treated with Laemmli buffer with 5% 2-Mercaptoethanol and boiled for 5
minutes prior to Western blot analysis.
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3.1.9 Immunoprecipitation
48 hours post transfection, HEK293T cells expressing either empty vector (EV),
TMPRSS13, and/or HAI constructs were lysed with RIPA lysis buffer with protease inhibitor
cocktail. One µl of primary mouse anti-V5 (Invitrogen, Life Technologies, Grand Island, NY) was
added to 150 µg of protein lysates and lysis buffer was added for a total reaction volume of 250
µl. Lysates were then rotated at 4ºC for 60 minutes. For HA immunoprecipitation, HEK293T
cells expressing HA-S506A-TMPRSS13 were lysed with RIPA lysis buffer with protease inhibitor
cocktail and equal amounts of lysates were separated and immunoprecipitated with either 1.0
µg of α-HA or α- Rabbit mAb IgG (DA1E – Cell Signaling Technology, Danvers, MA) antibodies
for 2 hours at 4ºC. For anti-intra-TMPRSS13 immunoprecipitation, whole lysates of DLD1 cells
were prepared with RIPA lysis buffer with protease inhibitor cocktail and 1.0 µg of anti-intra
TMPRSS13 or α- Rabbit mAb IgG was added to equal volume of lysates and rotated at 4ºC
overnight. After all immunoprecipitations, 30 µl of EZviewTM Red Protein A affinity gel (SigmaAldrich, St. Louis, MO) were added to the reaction per manufacturers protocol. Samples were
then rotated at 4ºC for an additional 60 minutes at which point beads were pelleted at 4ºC and
washed 5x with cold PBS pH 7.5. After the final wash, 60 µl of 2x Laemmli buffer with 5% 2Mercaptoethanol was added and samples were analyzed by SDS-PAGE and Western blotting.
3.1.10 Immunocytochemistry
Cell-surface imaging was performed using HEK293T cells transfected with human fulllength TMPRSS13-V5 vectors. Cells were seeded on coverslips coated with rat type-2 collagen
(BD Biosciences, Franklin Lakes, NJ) and allowed to adhere and grow overnight. Cells were
transiently transfected and 36 hours post transfection, media was removed and cells were fixed
in Z-Fix (ANATECH LTD, Battle Creek, MI) for 15 min at room temperature. In permeabilized
samples, cells were treated with 0.05% Triton-X in PBS. Cells were then blocked with 5% BSA
in PBS for 1 hour prior to staining. TMPRSS13-V5 was detected using a monoclonal anti-V5
antibody (Invitrogen, Life Technologies, Grand Island, NY) or an isotype control antibody
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(Sigma, St. Louis, MO). HAI-1 was detected using the M19 antibody (125) kindly provided by
Drs. Chen-Yong Lin and Michael Johnson, Georgetown University. Secondary AlexaFlour-488conjugated goat-anti-mouse and AlexaFlour-647-conjugated antibodies (Invitrogen, Life
Technologies, Grand Island, NY) were used to detect TMPRSS1-V5 and/or HAI-1. HAI-2 was
detected using a HAI-2-EYFP fusion protein (kindly provided by Dr. Stine Friis, University of
Copenhagen) (124). Cells were washed with PBS and mounted with Prolong gold with DAPI
(Invitrogen, Carlsbad, CA). Confocal images were acquired on the Zeiss LSM 780 scope at the
Microscopy Imaging and Cytometry Resources Core at Wayne State University School of
Medicine.
3.1.11 Biotin labeling of cell surface proteins
HEK293T cells expressing empty vector, TMPRSS13, and/or HAI constructs were
washed 3x with PBS 48 hours post transfection. Cells were then gently detached and resuspended in 1.0 ml of PBS, and EZ-Link Sulfo-NHS-SS-Biotin (Thermo Scientific, Waltham,
MA) was added for a final concentration of 800 µM. Cells were biotin-labeled for 30 minutes at
room temperature. After biotin labeling, cells were pelleted and washed 3x with PBS containing
50 mM Tris, pH 8.0. Cells were then lysed in RIPA buffer supplemented with protease inhibitor
cocktail (Sigma-Aldrich, St. Louis, MO) and protein concentrations were quantitated. 150 µg
protein were added to 40 µl streptavidin-agarose (Sigma-Aldrich, St. Louis, MO) in a final
reaction volume of 200 µl and rotated at 4ºC for 60 minutes. Beads were pelleted by
centrifugation at 8,800 x g and supernatant containing non-biotinylated proteins was collected
(wash). Beads were washed 5x with cold PBS and subsequently treated with 60 µl of Laemmli
Sample Buffer with 5% 2-Mercaptoethanol and boiled for 5 minutes prior to SDS-PAGE.
3.1.12 USP2 deubiquitination assay
HEK293T cells transfected with S506A-TMPRSS13-V5 were lysed 48 hours post
transfection in 450 µl RIPA buffer: 150 mM NaCl, 50 mM Tris/HCl, pH 7.4, 0.1% SDS, 1% NP40, supplemented with protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO). Lysates were
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aliquoted into

separate 1.5

ml microcentrifuge tubes

and USP2 catalytic domain

(BostonBiochem, Cambridge, MA) (final concentration of 2 µM) or vehicle was added. At 10,
30, 120, and 240 minutes after incubation, aliquots of the reaction were removed and treated
with Laemmli buffer supplemented with 5% 2-Mercaptoethanol and boiled for 5 minutes prior to
SDS-PAGE and Western blot analysis. Samples were run in parallel and TMPRSS13 was
detected using mouse anti-V5 (Invitrogen, Life Technologies, Grand Island, NY) and ubiquitin
was detected using rabbit anti-ubiquitin (Dako, Carpinteria, CA)
3.1.13 Glycosylation, intrinsic disorder, and phosphorylation predictions
NetNGlyc

1.0

Server

was

used

for

glycosylation

prediction

(http://www.cbs.dtu.dk/services/NetNGlyc/). To predict the disorder disposition we utilized the
PONDR-FIT analysis tool (http://disorder.compbio.iupui.edu/pondr-fit.php). The full-length
FASTA sequence for each corresponding protein was analyzed and the intracellular domains
were plotted on a single graph. Kinase Predictions. Three separate kinase prediction tools were
used to identify potential kinases responsible for TMPRSS13 phosphorylation. NetPhospho3.1
(http://www.cbs.dtu.dk/services/NetPhos/), GPS 3.0 (http://gps.biocuckoo.org/online.php) and
PhosphoNet (http://www.phosphonet.ca/).

For NetPhospho3.1 and GPS 3.0, the FASTA

sequences of the intracellular domains were analyzed.
3.2 Biochemical characterization of TMPRSS13 – Introduction
TMPRSS13 belongs to the type-II transmembrane serine protease (TTSP) family that
was discovered at the turn of the millennium (3,35,36,126). In humans, the family consists of 17
proteases divided into four subfamilies, based on phylogenetic analyses of their serine protease
domains and the domain structure of their extracellular stem regions (3,35,36,126). TMPRSS13,
also

known

as

mosaic

serine

protease

large-form

(MSPL),

belongs

to

the

hepsin/transmembrane protease, serine (TMPRSS) subfamily. TMPRSS13 contains an Nterminal intracellular domain, a transmembrane domain, a stem region, and a C-terminal serine
protease domain (127,128). The protease was originally cloned from a human lung cDNA library
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and transcripts were detected in lung, placenta, pancreas, and prostate (127). Subsequent
studies revealed a broad TMPRSS13 protein expression profile in epithelial tissue including
epidermis, oral cavity, esophagus, bladder, stomach, small intestine, thymus, kidney, and
cornea (65). A physiological role for TMPRSS13 in epidermal barrier development has been
demonstrated in TMPRSS13-deficient mice, which display improper formation of the cornified
layer of the epidermis (65). Furthermore, TMPRSS13 has been implicated in viral infection,
since it proteolytically cleaves the viral hemagglutinin (HA) protein, thereby enabling membrane
fusion of highly pathogenic avian influenza viruses and coronaviruses (129-131).
A defining characteristic of TTSPs is that they are synthesized as single-chain zymogens
that require proteolytic cleavage to generate the two-chain active proteases. Upon activation,
catalytic activity of several TTSPs, including matriptase, matriptase-2, hepsin, human airway
trypsin-like protease (HAT), and HAT-like 5, are inhibited by the endogenous, transmembrane,
Kunitz-type serine protease inhibitors, hepatocyte growth factor activator inhibitor (HAI-1) -1 and
-2 (55,132-134). A distinctive feature of TMPRSS13 is that it possesses the largest intracellular
domain of all the TTSP family members, consisting of 160 amino acids. Upon analysis of the
intracellular domain sequence, we

identified regions rich in proline, serine, and threonine

residues that are predicted to be intrinsically disordered regions (IDRs), which are natively
unfolded and do not adopt typical tertiary structures (135). IDRs are frequently subjected to
post-translational modifications, such as phosphorylation, that increase the functional state in
which a protein can exist in the cell (136). Here we describe a comprehensive study on the
biochemical and cell-biological properties of TMPRSS13 and report for the first time that
TMPRSS13 is a phosphorylated TTSP. Importantly, our results show that HAI-1 and HAI-2
enhance TMPRSS13 phosphorylation and facilitate cell surface localization.
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3.3 Biochemical characterization of TMPRSS13 – Results
3.3.1 TMPRSS13 is expressed as a 70 kDa glycosylated active protease in mammalian
cells
Like other TTSPs, TMPRSS13 contains a C-terminal catalytic serine protease (SP)
domain, an N-terminal intracellular domain, a transmembrane signal anchor, and a stem region.
The stem region in TMPRSS13 is composed of a group A scavenger cysteine-rich receptor
(SRCR) domain, preceded by a single, low-density lipoprotein receptor class A domain (LDLA)
(Fig. 1A, panel I). The catalytic domain of human TMPRSS13 contains the essential serine
protease catalytic triad residues, H361, D409, S506, and the substrate binding pocket
residues, D500, S525 and G527(129).

TTSP’s are universally synthesized as inactive zymogens

that are activated by cleavage at a conserved activation site motif, predicted to be R320IVGG in
TMPRSS13 (indicated with an arrow in Fig. 2A, panel I) (127,129). Upon activation, the catalytic
domain remains tethered via a disulfide bond to the stem region of the protease. Therefore, the
active SP-domain can be visualized by SDS-PAGE and Western blotting under reducing
conditions. In a previous study, using recombinant TMPRSS13 in which the putative activation
cleavage sequence was replaced with the enterokinase recognition sequence (DDDDK),
activation with enterokinase under cell-free conditions was achieved and TMPRSS13 displayed
proteolytic activity towards synthetic peptide substrates (66). However, this earlier work did not
examine whether this phenomenon applies in a cellular environment. To determine whether
TMPRSS13, containing its native activation sequence, is expressed as an active protease in
mammalian cells, we expressed full-length human TMPRSS13 in HEK293T cells and analyzed
whole cell lysates by Western blotting (Fig. 2B) using an anti-TMPRSS13 polyclonal antibody
raised against the extracellular part of the TMPRSS13 antibody (α-extra-TMPRSS13, indicated
in 2A, panel I). The predicted molecular weights of the 586 amino acid full-length protease and
the 266 amino acid SP-domain are 61 kDa and 27 kDa, respectively. Two major proteins of
approximately 70 kDa and 32 kDa were detected in lysates (Fig. 2B). These species migrated
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Figure 2: TMPRSS13 is a 70-kDa active glycoprotein in
human cells.

Figure 2. (A) Schematic representation of the four different recombinant TMPRSS13 proteins
generated for this study. (I) Full-length human TMPRSS13 (WT-TMPRSS13);
TM=Transmembrane domain, L=lipoprotein receptor class A domain, SRCR= group A
scavenger cysteine-rich receptor, N=predicted N-glycosylation sites, the activation cleavage site
is indicated with an arrow, and S-S represents the disulfide bridge linking the stem region to the
serine protease (SP) domain. The epitopes for the two anti-TMPRSS13 antibodies used are
indicated. A polyclonal antibody raised against a recombinant protein fragment corresponding to
a region within amino acids 195 and 562 of Human TMPRSS13, (α-extra-TMPRSS13), that
recognizes the extracellular part of the protease. An additional polyclonal antibody, (αTMPRSS13-intra), was raised against a peptide within residues 1-60 which recognizes the Nterminal intracellular domain. (II) C-terminally tagged full-length human TMPRSS13 (WTTMPRSS13-V5); V5-H=V5-His epitope. (III) Active soluble TMPRSS13 serine protease domain
protein generated in Pichia Pastoris. (IV) N-terminally HA-tagged full-length human TMPRSS13
(HA-WT-TMPRSS13); HA=Human influenza hemagglutinin tag. (B) Whole cell protein lysates
from HEK293T cells, expressing non-tagged full-length human TMPRSS13 were separated by
SDS-PAGE under reducing conditions. TMPRSS13 was detected by Western blotting using the
rabbit α-extra-TMPRSS13 antibody against the extracellular part of TMPRSS13. Nontransfected cells (NT) and cells transfected with empty vector (EV) were included as controls.
The full-length TMPRSS13 and SP-domain are indicated with black arrowheads and full-length
glycosylation and cleavage variants are indicated with open arrowheads. (C-D) Proteins were
separated by SDS-PAGE and analyzed by Western blotting using α-extra-TMPRSS13 (C) and
α-intra-TMPRSS13 (D), respectively. Lanes with protein extracts treated with PNGaseF prior to
SDS-PAGE are indicated with “+”, and control extracts treated and incubated in parallel without
PNGaseF with “-“, NT=No treatment. The white arrowheads connected to black arrowheads
indicate the reduction in apparent molecular weight of the glycosylated forms of TMPRSS13.
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Figure 3: Detection of TMPRSS13 under different expression
concentrations and sample collection methods

Figure 3. (A) HEK293T cells transfected were transfected with WT, - or S506A-TMPRSS13-V5
at the plasmid concentrations indicated resulting in different expression levels of recombinant
TMPRSS13. Lysates were made in stringent lysis buffer (1.5% SDS and 100 mM DTT) that had
been pre-boiled for 10 minutes prior to addition to cells. Lysates were separated by SDS-PAGE
under reducing conditions followed by Western blot analysis using an α-V5 antibody. (B) Whole
lysates from HEK293T cells transfected with WT, - or S506A-TMPRSS13-V5 were prepared
using RIPA buffer with protease inhibitor cocktail at 4oC, or stringent SDS buffer, and analyzed
as described in (A).
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at higher molecular weights than predicted for the full-length and SP-domain, suggesting that
TMPRSS13 could be post-translationally modified. Analysis of the amino acid sequence of
human TMPRSS13 using the NetNGlyc 1.0 Server revealed four potential N-glycosylation sites,
two of which are located in the serine protease domain (Fig. 2A). In addition to the 70 kDa and
32 kDa species, two forms of approximately 60 kDa and 50 kDa were recognized by the α-extraTMPRSS13 antibody in whole cell lysates (Fig. 2B). To minimize the risk of cleavage events
occurring as a result of cell lysate preparation, or due to high levels of recombinant TMPRSS13
expression, we analyzed cell lysates with low expression levels and lysates prepared using
highly stringent conditions (boiling in 1.5% SDS with 100 mM DTT; Fig. 4A and B). We did not
observe any discernible differences in protein band pattering by Western blotting between
TMPRSS13 low- and high-expressing cells (Fig. 3A). Furthermore, no noticeable differences
were observed when cell lysis was performed in RIPA buffer versus stringent SDS buffer (Fig.
3B).
To examine whether TMPRSS13 is post-translationally modified by glycosylation in
mammalian cells, protein extracts from transfected HEK293T cells were subjected to enzymatic
deglycosylation by PNGaseF prior to Western blot analysis and probed with α-extra-TMPRSS13
(Fig. 2C). Upon deglycosylation and probing with α-extra-TMPRSS13, we observed a reduction
in the molecular weight of the proposed full-length 70 kDa form, to a form closer to the predicted
lower molecular weight (∼60 kDa); this band coincides with the 60 kDa species seen before
deglycosylation. These results indicate that the full-length form of TMPRSS13 exists as two
different glycosylation variants (Fig. 2C). The presumed SP-domain shifted to the predicted
molecular weight upon deglycosylation, indicating that one or both of the potential N-linked
glycosylation sites in the SP-domain are utilized (Fig. 2C).

The 50 kDa band migrated at

approximately 40 kDa and may represent an ectodomain cleavage product generated upon
cleavage in the LDLA domain of the stem region. Several TTSPs have been shown to be
cleaved in the stem region including corin, where two fragments result from corin autocleavage
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in the frizzled 1 domain and LDLA 5 domain, respectively (137). The cleavage event generating
the 50 kDa TMPRSS13 species appears to be dependent on TMPRSS13 proteolytic activity
since the fragment is not detected in cells transfected with a catalytically inactive from of
TMPRSS13 and may result from autocleavage (Fig. 3B). Deglycosylated lysates were also
analyzed using an antibody raised against a peptide localized within the first 60 (N-terminal)
amino acids (α-intra-TMPRSS13) as indicated in the schematic representation of TMPRSS13 in
Figure 2A. Similarly to α-extra-TMPRSS13, we observed the 70 kDa form drop to 60 kDa upon
deglycosylation (Fig. 2D). In addition, other N-terminal processed forms of approximately 43
kDa and 22 kDa are observed. The latter may result from cleavage within the LDLA domain, i.e.
represent the N-terminal half of the C-terminal 50 kDa half detected with α-extra-TMPRSS13 in
Fig. 2C.
In addition to whole cell lysates, conditioned media (CM) samples collected from the
same cells were analyzed. One band corresponding to the predicted SP-domain was detected
in cells transfected with full-length TMPRSS13 (Fig. 4A) suggesting that TMPRSS13 is shed
mainly in its active form. To validate that the SP-domain is in fact a catalytically active serine
protease, we performed an α2-macroglobulin (α2M) capture assay (Fig. 4B). Incubation of α2M
with CM from cells expressing full-length TMPRSS13 resulted in the formation of a TMPRSS13
high molecular weight complex, consisting of TMPRSS13 SP-domain covalently linked to α2M
subunits, indicating that expression of TMPRSS13 in mammalian cells produces a catalytically
active serine protease (Fig. 4B).
To further confirm the enzymatic activity of the TMPRSS13 SP-domain, the Pichia
pastoris expression system which utilizes the intracellular yeast protease KEX2 was employed.
The KEX2 transmembrane serine protease belongs to the subtilisin-like, pro-protein convertase
family with specificity for cleavage after paired basic amino acids and is localized in the late
Golgi compartment. By cloning the TMPRSS13 SP-domain into the PIC9 vector with the
TMPRSS13 active serine protease domain sequence (321IVG) immediately following the LGKR
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Figure 4: Proteolytic activity of TMPRSS13 serine protease
domain

Figure 4. (A) Conditioned media from untreated cells (NT), or cells transfected EV or nontagged full-length human TMPRSS13 were analyzed by Western blotting. Only the SP-domain
is detected. (B) To determine whether the TMPRSS13 SP-domain is secreted into conditioned
medium as an active protease, an α2-M capture experiment was performed and samples were
separated by SDS-PAGE under reducing conditions, and detected by Western blotting using αextra-TMPRSS13. The positions of the non-complexed TMPRSS13 SP-domain (black
arrowhead) and the SP-domain/α2-M complex (open arrowhead) are indicated. (C) Detection
of the SP-domain in conditioned media from Pichia pastoris expressing cleaved, active
TMPRSS13 with (+) and without (-) PNGaseF treatment by reducing SDS-PAGE and Western
blotting (left panel). The white arrowheads connected to black arrowheads indicate the
reduction in molecular mass of the glycosylated form of the SP-domain. Bar graph, right panel;
Conditioned media samples from Pichia pastoris clones transfected with either the expression
vector without protease insert (EV),TMPRSS13 SP-domain, or matriptase SP-domain were
incubated at 37 °C for 60 min with the synthetic chromogenic peptide Suc-Ala-Ala-Pro-Arg-pNA
(100 μm) and the absorbance at 405 nm was recorded. Negative control (Neg. control) lane
contains buffer and peptide with no media added.
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KEX2 cleavage site encoded by the vector, a novel fusion cleavage site was generated (Fig. 2,
panel III, see arrow indicating cleavage site). The new LGKR|IVG sequence is cleaved between
R and I by KEX2, generating a secreted active TMPRSS13 SP-domain with the same IVG Nterminus as mammalian active SP-domain (Fig. 2, panels I and III). The presence of
TMPRSS13 serine protease in conditioned media from Pichia pastoris clones transfected with
the PIC9-TMPRSS13 vector was confirmed by Western blotting using the polyclonal α-extraTMPRSS13 antibody (Fig. 4C, left panel). Deglycosylation of the untagged, cleaved, active form
of the TMPRSS13 SP-domain, secreted by transfected Pichia pastoris, results in a form with an
apparent molecular weight of ∼29 kDa (Fig. 4C, left panel). This indicates that both human and
yeast-expressed active serine protease domain migrate at the same approximate molecular
weight upon deglycosylation. The catalytic activity of TMPRSS13 SP-domain was confirmed
using the serine protease chromogenic peptidolytic substrate Suc-Ala-Ala-Pro-Arg-pNA (Fig.
4C, right panel). Conditioned media from cells transfected with empty PIC9 vector was included
as a negative control to ensure the absence of interfering secreted yeast proteases, and the
well-characterized TTSP, matriptase, which was produced in parallel in Pichia pastoris, was
included as positive control. Collectively, these data demonstrate that TMPRSS13 is a
glycosylated protease with peptidolytic activity.
3.3.2 Catalytic inactivation of TMPRSS13 promotes TMPRSS13 cell surface localization
Analysis of the TMPRSS13 protein sequence using the TMHMM Server v. 2.0 reveals
the presence of a single transmembrane domain, predicting that the TMPRSS13 protein, similar
to previously characterized members of the TTSP family, will localize on the cell surface
(3,36,126,129). To investigate the cellular localization of TMPRSS13, HEK293T cells transiently
expressing the wild type (WT) full-length protease with a C-terminal V5-tag (WT-TMPRSS13V5) (Fig 1A, panel II) were analyzed by fluorescent immunocytochemistry. To detect the
localization of WT-TMPRSS13-V5, an anti-V5 antibody was used on non-permeabilized cells in
combination with a FITC-conjugated secondary antibody to visualize cell surface TMPRSS13.
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Interestingly, little to no WT-TMPRSS13-V5 was detected under non-permeabilized conditions
(Fig.5A, top left panel). In contrast, intense green fluorescent signal confined to the cytoplasm
in permeabilized cells was observed, indicating that the majority of WT-TMPRSS13-V5 is
retained within the cells (Fig. 5A, bottom left panel). When primary antibodies were substituted
with non-immune IgG, no detectable staining was observed (Fig. 5A right panels).

Since

untagged, WT-TMPRSS13 appeared to be present in its active form in lysates and CM as
demonstrated by Western blotting above (Figs. 2B and 3A), we speculated that the active
protease fails to properly localize to the cell surface due to the deleterious effects of unopposed
proteolytic activity. To test this possibility, we utilized a catalytically inactive form of TMPRSS13
(S506A-TMPRSS13-V5) where the serine in the catalytic triad is mutated to an alanine (Fig.
5B). In addition, we also generated a “zymogen-locked” form (R320Q-TMPRSS13-V5) in which
the conserved activation site is mutated to prohibit activation cleavage. Upon transfection, both
S506A- and R320Q- TMPRSS13-V5 clearly localized to the cell surface in both permeablilized
and non-permeabilized cells (Fig. 5B and 5C). This observation is in agreement with the
expected distribution of the predicted membrane anchored topology of TMPRSS13, indicating
that catalytically incompetent TMPRSS13 primarily localizes to the cell surface.
Lysates of transfected cells were then examined by Western blotting to analyze the state
of WT-TMPRSS13-V5 compared to the two mutant versions. To ensure that WT-TMPRSS13V5 exists in its intact full-length form with both the N- and C-terminus present, we probed with αintra-TMPRSS13 and α- -V5 (Fig. 5D). The two full-length glycosylation variant forms (~65 and
~75 kDa, which include the ~5 kDa V5-tag) were detected in WT-TMPRSS13, as well as in
S506A- and R320Q- TMPRSS13-V5 with both antibodies. Thus, the C-terminal V5 tag appears
intact and the N-terminus is most likely intact since the α-intra-TMPRSS13 antibody was raised
against an N-terminal peptide. Surprisingly, in lysates from cells expressing S506A- or R320QTMPRSS13-V5 (Fig. 5D) an additional, prominent and higher molecular weight (HMW)
TMPRSS13 form of ~95 kDa was observed. This HMW species was resistant to extraction in
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Figure 5: Catalytic inactivation of TMPRSS13 promotes its
cell surface localization and produces a higher molecular
weight TMPRSS13 species

Figure 5. HEK293T cells were transiently transfected with full-length human WT-TMPRSS13V5 (A), S506A-TMPRSS13-V5 (B), or R320Q-TMPRSS13-V5 (C) expression plasmids. Nonpermeabilized cells (upper panels) or permeabilized cells (lower panels) were incubated with an
anti-V5 antibody, followed by incubation with FITC-labeled secondary antibodies and DAPI
staining to visualize nuclei. The cells were visualized by confocal fluorescence microscopy at
351– 364 nm excitation wavelength (DAPI) or 488 nm (FITC). Merged images obtained at the
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two excitation wavelengths are shown. Non-immune IgG was included instead of anti-V5 as
negative controls. (D) Protein lysates from HEK293T cells expressing empty vector (EV), WTTMPRSS13-V5, S506A-TMPRSS13-V5, or R320Q-TMPRSS13-V5 were analyzed by Western
blotting using the α-intra-TMPRSS13 antibody recognizing the N-terminus, or α-V5 recognizing
the C-terminus. The higher molecular weight (HMW) species is indicated with grey arrowhead.
(E) Cell surface proteins of HEK293T cells expressing either HA-WT-TMPRSS13, or HAS506A-TMPRSS13 were biotin labeled at room temperature for 30 minutes. Biotin labeled cell
surface proteins were separated from non-labeled proteins by incubation with streptavidin
agarose for 60 minutes at 4ºC. The streptavidin agarose beads were then pelleted and the
supernatant containing proteins not precipitated by streptavidin agarose was collected (wash
lane). Biotin labeled proteins were eluted from the beads by addition of Laemmli sample buffer
with 5% 2-Mercaptoethanol. Samples were separated by SDS-PAGE and analyzed by Western
blot using an α-HA antibody.
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RIPA buffer followed by boiling in Laemmli sample buffer with 5% 2-Mercaptoethanol (Fig. 5D)
and to extraction under stringent conditions (1.5% SDS with 100 mM DTT) (Fig. 3B), suggesting
the possibility of covalent post-translational modifications, in addition to glycosylation, in two
different catalytically incompetent forms of TMPRSS13. To further validate these findings, we
analyzed lysates from cells expressing TMPRSS13 with an N-terminal HA-tag (depicted in Fig.
1, Panel IV, HA-WT-TMPRSS13) in combination with cell-surface biotinylation analysis using a
membrane-impermeable biotinylation reagent (Fig. 5E). Cell surface biotinylated proteins were
pulled down using streptavidin agarose. In accordance with the observations above, the fulllength HA-WT-TMPRSS13 species (~65 and~75 kDa) were detected with an α-HA antibody in
whole lysates confirming that the ~65 and ~75 kDa species both contain an intact N-terminus.
The HMW form of TMPRSS13 was also detected with the α-HA antibody in lysates expressing
the HA-tagged S506A mutant (Fig. 5E, right panel) thereby confirming that the ~65, ~75 kDa
and ~95 kDa are all full-length proteins that contain both the N- and C-termini. The biotinylation
assay confirmed that WT-TMPRSS13 is not present in detectable amounts in the cell surface
fraction (Fig. 5E, left panel) while S506A -TMPRSS13 is readily detected on the cell surface
(Fig. 5E, right panel), mainly it its HMW form. Detailed characterization of the HMW form is
described below in the section “TMPRSS13 is phosphorylated”.
3.3.3 TMPRSS13 is capable of auto-activation
We consistently observed decreased detection of the cleaved active SP-domain in
S506A-TMPRSS13 expressing cells in comparison to the levels of the active species seen in
cells transfected with WT-TMPRSS13 (Fig. 6A). Quantitative ratio comparisons of the active
(SP-domain) versus inactive full-length forms of TMPRSS13 confirmed that the majority of
TMPRSS13 in S506A-TMPRSS13 expressing cells is in its inactive full-length forms (Fig. 6B).
These data indicate that TMPRSS13 proteolytic activity is important for its own activation and
that TMPRSS13, like several other TTSPs, is likely capable of auto-activation. To further
explore the possibility of auto-activation, intact cells transfected with S506A-TMPRSS13-V5
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Figure 6: TMPRSS13 is proteolytic activity promotes its own
activation

Figure 6. (A) Protein lysates from HEK293T cells expressing empty vector (EV), WTTMPRSS13, or S506A-TMPRSS13 were analyzed by reducing SDS-PAGE and Western using
the α-extra-TMPRSS13 antibody. (B) Graph depicting the relative ratios of staining intensity
after Western development of active TMPRSS13 (SP-domain) compared to the inactive (fulllength) species from three separate experiments. P < 0.05, student's t test (C) Cells
expressing S506A-TMPRSS13-V5 were mechanically lifted from the plates by gentle pipetting in
PBS, pelleted by centrifugation at 1,000 x g and re-suspended in PBS pH 7.4 (57). Cells were
then incubated with 100 nM active recombinant matriptase, prostasin, or TMPRSS13 or left
untreated (no treatment lane), and incubated at 37ºC for 30 minutes. After incubation, cells
were pelleted by centrifugation at 1,000 x g and supernatant was collected. Cells were then
washed 5 times with PBS. After the last wash cells were lysed with RIPA lysis buffer with
protease inhibitor cocktail and analyzed by Western blotting under reducing conditions.
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were treated with soluble recombinant SP-domain of TMPRSS13, prostasin, or matriptase (Fig.
6C). After protease treatment, cells were pelleted by centrifugation and the supernatant was
collected to detect TMPRSS13 released by shedding. Treatment of cells with exogenous, active
TMPRSS13 SP-domain led to robust activation as evidenced by detection of the SP-domain in
lysates and supernatant. The TMPRSS13 SP-domain is the result of cleavage and activation of
full-length, S506A-TMPRSS13-V5 and not detection of the exogenous Pichia Pistoris active SPdomain since the recombinant Pichia Pistoris active SP-domain lacks the V5 epitope. The
active, recombinant SP-domain from prostasin, a non-TTSP, GPI-anchored cell surface serine
protease, had no effect whereas a low level of TMPRSS13 SP-domain was detected upon
treatment with the TTSP, matriptase, in lysates with abundant SP-domain in the supernatant.
Interestingly, the HMW form of TMPRSS13 appears to be preferentially cleaved by both
TMPRSS13 and matriptase, which indicates that this form is likely accessible on the cell surface
to exogenously added protease. This is in agreement with the biotinylation assay using HAS506A-TMPRSS13 which demonstrates that the HMW species is the primary species observed
at the cell surface (Fig. 5E).
3.3.4 TMPRSS13 is phosphorylated
To characterize the HMW form of TMPRSS13, we first performed deglycosylation of
lysates from cells expressing untagged S506A- or R320Q-TMPRSS13, which resulted in the
HMW species to migrate at ~73 kDa, which is ~13 kDa greater than the full-length
deglycosylated TMPRSS13 (Fig. 7A). This confirms that the HMW form is subject to additional
post-translational modification(s). Initial tests were conducted to determine whether the HMW
form represents a ubiquitinated species of TMPRSS13, since mono-ubiquitination is a common
covalent post-translational modification of cell surface proteins that results in the attachment of
the ~8.5 kDa ubiquitin protein (138).

Deubiquitination of whole cell lysates using the

recombinant catalytic domain of deubiquitinase USP2 (139-141) did not result in a mobility shift
of the HMW species (Fig.8A). Only two lysine residues exist in the intracellular domain of
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Figure 7: TMPRSS13 is a phosphorylated TTSP family
member
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Figure 7. (A) Protein lysates from cells expressing S506A- or R320Q-TMPRSS13 were either
untreated (NT) or treated with PNGaseF (+) or without (-) (incubated in deglycosylation buffer
minus PNGaseF) for 60 min at 37oC prior to reducing SDS-PAGE and Western blotting using αextra-TMPRSS13. The white arrowheads connected to black arrowheads indicate the reduction
in apparent molecular weight of the glycosylated forms of TMPRSS13. (B) Graph representing
the intrinsic disorder of Hepsin/TMPRSS family member’s intracellular domains. Full-length
FASTA sequences of hepsin, TMPRSS2, TMPRSS3, TMPRSS4, spinesin, and TMPRSS13
were analyzed using PONDR-FIT (142) and the intracellular domains were plotted on a single
graph for comparison. The blue line represents TMPRSS3 overlaying TMPRSS4 (turquoise line)
since the profiles of the two are virtually identical. The final X-axis data point for each protein
indicates the last amino acid of the intracellular domain. (C) Amino acid sequence of the 160
amino acid proline (26 residues, red) and serine rich (30 residues, blue) intracellular domain of
TMPRSS13. (D) Two different exposures of Western blot analysis of lysates from cells
expressing WT-TMPRSS13, S506A-TMPRSS13-V5, or R320Q-TMPRSS13-V5 that were
treated with or without CIP and incubated at 37ºC for 60 minutes. (E) Lysates from HEK293T
cells expressing HA-S506A-TMPRSS13 were immunoprecipitated using an α-HA or an α-IgG
control antibody. Samples were separated in parallel and analyzed by Western by probing with
α-phospho-serine/threonine or α-HA antibodies.
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Figure 8: TMPRSS13 is not ubiquitinated

Figure 8. (A) Lysates from cells expressing S506A-TMPRSS13-V5 were treated (+) with the
deubiquitinase USP2 or vehicle (-) for 0, 10, 30, or 240 minutes. At each time point the samples
were boiled in Laemmli sample buffer with 5% 2-Mercaptoethanol for 5 minutes prior to Western
blot analysis. A parallel Western blot was probed using anti-ubiquitin to ensure USP2 activity.
Efficient deubiquitination is observed after 10 min (lower right panel) but no shift of the ~95 kDa
is observed. (B) The two lysine residues within the intracellular domain of TMPRSS13 were
mutated in S506A-TMPRSS13-V5 to arginine (K151R-K159R-S506A-13-V5) to prevent
potential ubiquitination of TMPRSS13. Mutant constructs were expressed in HEK293T cells and
protein lysates were analyzed by Western blotting. No change in the migration or expression
level of the ~95 kDa species is observed.
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TMPRSS13 and upon mutation to prevent ubiquitin modification (K151R and K159R) no effect on
the abundance or size of the HMW species was observed (Fig. 8B). Taken together, these
observations strongly indicate that ubiquitination does not contribute to the HMW form of
TMPRSS13.
Currently, the only reported post-translational modifications of other Hepsin/TMPRSS
family members are glycosylation and proteolytic cleavage (3). Other types of post-translational
modifications, including phosphorylation, are often found in transmembrane proteins that
contain IDRs (143,144). Intrinsic disorder occurs in ~50% of transmembrane proteins and
proteins with IDRs are more likely to be phosphorylated than proteins that lack them (143).
Therefore, we conducted computational prediction of IDRs within the intracellular domain of
TMPRSS13 and four additional TMPRSS/Hepsin family members using PONDR-FIT (142) to
determine whether there is a higher degree of disorder in the intracellular domain of TMPRSS13
compared to the other family members (Fig. 7B). The comparative analysis revealed that a large
segment of TMPRSS13, the first 125 amino acids, displays a high degree of disorder followed
by a sharp decline to a lower disorder disposition before the beginning of the transmembrane
domain (Fig. 7B). In comparison, the intracellular domain of TMPRSS2, which contains the
second longest intracellular domain of the Hepsin/TMPRSS family, contains a short segment of
only 10 amino acids with a high degree of disorder before a sharp decline (Fig. 7B). IDRs are
also often enriched in disorder promoting amino acid residues such as proline (P), and serine
(S) (24); the intracellular domain of TMPRSS13 contains 15% proline and 19% serine residues
(Fig. 7C). In sum, TMPRSS13 contains the largest intracellular domain with a higher degree of
intrinsic disorder compared to other Hepsin/TMPRSS family members. Based on this
observation and on the fact that transmembrane proteins that contain IDRs are frequently
phosphorylated (3,143,144), we investigated whether the HMW species represents a
phosphorylated form of full-length TMPRSS13.
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Phosphorylation of proteins occasionally causes mobility shifts in Western blot analysis
due to the negative charge of the covalently attached phosphate group, thereby reducing
negatively charged SDS from interacting with the phosphorylated protein (145). Whole lysates
from cells expressing WT, - R320Q, - or S506A-TMPRSS13-V5 were dephosphorylated by
treatment with calf intestinal alkaline phosphatase (CIP) and separated by SDS-PAGE. Western
blot analysis of the CIP-treated samples revealed a mobility shift of the HMW form (Fig. 7D)
indicating that the higher molecular weight product is a full-length phosphorylated and
glycosylated TMPRSS13 species. Of note, dephosphorylation did not reduce the HMW species
to the identical molecular weight of the non-phosphorylated V5-tagged full-length species of ~75
kDa. A possible reason for this may be that the phosphorylated species is differentially
glycosylated compared to the non-phosphorylated full-length, or that dephosphorylation of
lysates results in incomplete removal of total phosphorylated residues of the intracellular
domain.
The intracellular domain of TMPRSS13 contains a total of 30 serine, 12 threonine, and 1
tyrosine residue(s). Previous reports indicate that transmembrane proteins that contain IDRs,
like TMPRSS13, are more likely to have greater than 10 phosphorylation sites than proteins that
lack IDRs (143). Since it is likely that one or more serine or threonine residues are
phosphorylated, and to confirm the phosphorylation of the HMW TMPRSS13 species,
immunoprecipitation of lysates from cells expressing HA-S506A-TMPRSS13 was performed.
Affinity pull-downs of HA-S506A-TMPRSS13 with α-HA followed by immunoblotting with an αHA antibody, and an antibody specifically recognizing phospho-serine/threonine residues,
confirmed that the HMW species is phosphorylated. (Fig. 7E). As expected, probing with α-HA
reveals both full-length TMPRSS13 and phosphorylated TMPRSS13 (Fig. 7E, left panel). When
α-Phospho-Ser/Thr was used for detection, a single band corresponding to HMW TMPRSS13
was detected (Fig. 7E, right panel). Together, these data show that HMW TMPRSS13
represents a phosphorylated form of the protease.
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3.3.5 Endogenous TMPRSS13 is phosphorylated and glycosylated
To determine whether endogenous TMPRSS13 is present in a phosphorylated form, the
human breast cancer cell lines HCC1937, MCF-7, and BT-20, as well as the colorectal
adenocarcinoma cell line DLD1 were screened for expression of TMPRSS13 by Western
blotting. Lysates were analyzed side-by-side with untagged WT- or S506A-TMPRSS13 for
comparison and detected with the α-intra-TMPRSS13 (Fig. 9A and Supplementary 1) We
observed bands corresponding in size to the glycosylated full-length (~70 kDa), a nonglycosylated full-length (~60 kDa), as well as a HMW TMPRSS13 (~90 kDa) in all four cell lines,
with varying amounts of HMW TMPRSS13 relative to total TMPRSS13 among the different cell
lines (Fig. 5A).We also analyzed the expression of the endogenous Kunitz-type serine protease
inhibitors, HAI-1 and HAI-2 in these cell lines, which are critical regulators of proteolytic activity
of several TTSP family members (3,36,126). Lysates of cell lines were analyzed by Western
blotting and probed for TMPRSS13, HAI-1, and HAI-2. Both inhibitors were detected in all four
cell lines (Fig. 9B). To ensure α-intra-TMPRSS13 antibody specificity, TMPRSS13 was knocked
down in the MCF-7 (Fig. 9C, left) and DLD1 cells lines (Fig. 9C, right) using two different nonoverlapping siRNAs targeting the TMPRSS13 transcript. At 72 hours after siRNA transfection,
cells lysates were analyzed by Western blotting. Levels of endogenous, full-length TMPRSS13
and the HMW species of ~90kDa TMPRSS13 were significantly reduced upon TMPRSS13
silencing, confirming that the antibody is suitable to study endogenous TMPRSS13 (Fig. 9C).
To determine whether the ~90kDa product of the endogenous form of TMPRSS13 is a
phosphorylated species in MCF-7 and DLD1 cells, whole cell lysates were dephosphorylated
with Lambda Protein Phosphatase (lambda PP) (Fig. 9D).

Dephosphorylation of lysates

resulted in a mobility shift of the ~90kDa band, indicating that the HMW species is a
phosphorylated endogenous TMPRSS13 species. To additionally validate that endogenous
HMW TMPRSS13 represents the phosphorylated form of the protease, immunoprecipitation of
whole lysates from DLD1 cells using the α-intra-TMPRSS13 was performed. Isolated proteins
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Figure 9: Endogenous TMPRSS13 is phosphorylated

Figure 9. (A) Lysates from HEK293T cells expressing untagged WT-TMPRSS13 or
S506A-TMPRSS13 were analyzed side by side with lysates from the breast cancer cell lines
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MCF7, BT20, and HCC1937, and the colorectal carcinoma cell lines DLD1. The figure shows a
short exposure (left) for the exogenously expressed TMPRSS13, and a long exposure (right) for
the endogenously expressed TMPRSS13 to compare sizes. Original Western blot exposures
can be found in supplementary Fig. 21A. Asterisk indicates non-specific bands (B) Lysates from
the indicated cell lines were analyzed for expression of TMPRSS13, HAI-1, and HAI-2. Asterisk
indicates non-specific bands. (C) MCF-7 and DLD-1 cells were treated with two nonoverlapping RNA duplexes (siRNA 31 and 33) targeting the TMPRSS13 transcript or a
scrambled GC-matched control (SCRM). After 72 hours post-treatment, cells were lysed and
analyzed by Western blotting to analyze decreased expression of TMPRSS13. Asterisk
indicates non-specific bands. (D) MCF-7 and DLD-1 cell lysates treated with (+) or without (-)
lambda phosphatase and analyzed by Western blotting to detect endogenous TMPRSS13 using
the α-intra-TMPRSS13 antibody under reducing conditions. (E) DLD-1 cell lysates were
immunoprecipitated with either α-intra-TMPRSS13 or α-IgG control. Precipitated samples were
separated in parallel and analyzed by Western by probing for either α-phospho-serine/threonine
or α-intra-TMPRSS13. Input lane contains samples from lysates prior to immunoprecipitation.
(F) Lysates from DLD1 or MCF-7 cells were treated with (+) or without (-) PNGaseF and
analyzed by Western under reducing conditions
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were analyzed by Western blotting and upon probing with anti-Phospho-Ser/Thr, a band
corresponding to HMW TMPRSS13 was detected (Fig. 9E, right panel). Taken together these
data indicate that the ~90 kDa species is representative of an endogenous phosphorylated
TMPRSS13 species.
To assess the glycosylation status of endogenous TMPRSS13, lysates from MCF and
DLD1 cells were deglycosylated with PNGaseF for 60 minutes (Fig. 9F). In the control lane (-)
two bands of ~70 kDa and ~60 kDa are observed; upon deglycosylation (+ lane) two bands of
~60 kDa and 58 kDa are observed. It is likely that the ~70 kDa band is reduced to the ~60 kDa
species since similar observations are seen upon deglycosylation of TMPRSS13 in HEK293T
cells (Fig. 2D). Notable, upon deglycosylation is the presence of two bands, which may
represent two different TMPRSS13 isoforms rather than two different glycosylated full-length
species. Currently there are two known TMPRSS13 isoforms that have been identified in lung,
placenta, pancreas, prostate and testis (5). Deglycosylation of lysates that expressed high
levels of detectable endogenous phosphorylated TMPRSS13 revealed that the phosphorylated
species shifts from ~90 kDa to ~73 kDa (Supplementary Fig. 21B) which is similar to what we
observed upon deglycosylation of S506A-TMPRSS13 (Fig. 7A). Collectively, these results
demonstrate that endogenous TMPRSS13 is post-translationally modified by glycosylation and
phosphorylation.
3.3.6 HAI-1 and HAI-2 mediate TMPRSS13 cell-surface localization and phosphorylation
The data above indicate that loss of TMPRSS13 proteolytic activity, either directly by
mutation of a residue within the catalytic triad, or indirectly, by mutation of the activation site,
results in a detectable, phosphorylated, full-length form of TMPRSS13 and its cell surface
localization. The Kunitz-type serine protease inhibitors, HAI-1 and HAI-2, are critical regulators
of proteolytic activity of several TTSP family members (3,36,126) and play a role in proper cellsurface localization (124,146,147). As shown in Fig. 9B, the cancer cell lines DLD1, BT20,
HCC1937, and MCF7 all express endogenous HAI-1 and HAI-2. Therefore, we reasoned that
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HAI-1 and/or HAI-2 could facilitate TMPRSS13 phosphorylation and cell surface localization. To
test the inhibitory activity of HAI-1 and HAI-2 towards TMPRSS13, we performed a peptidolytic
assay using active recombinant TMPRSS13 SP-domain, generated in Pichia Pastoris, with
known inhibitors of TTSP family members including HAI-1, HAI-2, aprotinin, leupeptin, and
benzamidine. The test was performed in parallel with active matriptase SP-domain, generated in
the same expression system, for comparison with a well-characterized reference protease and
to ensure inhibitor activity (132) (Fig. 10A). Active TMPRSS13 or matriptase were incubated
with the chromogenic peptide Suc-Ala-Ala-Pro-Arg-pNA in the absence or presence of the
indicated serine protease inhibitors (inhibitor and substrate added concomitantly) and changes
in absorbance were analyzed. Similar to previous reports, recombinant HAI-1 and HAI-2 both
inhibit matriptase activity (132,148,149). HAI-1 appeared to be a poor inhibitor of TMPRSS13
activity in this in vitro setting, whereas incubation with HAI-2 resulted in nearly complete loss of
measurable proteolytic activity. This is similar to previous reports where HAI-1, containing both
Kunitz inhibitory domains, displayed weak inhibitory activity towards recombinant TMPRSS13
compared to HAI-2 in a cell-free assay (66). We also observed TMPRSS13 inhibition with the
globular polypeptide, Kunitz-type serine protease inhibitor, aprotinin (bovine pancreatic trypsin
inhibitor) and leupeptin, whereas benzamidine was a poor inhibitor of TMPRSS13 in this assay.
To validate the HAI-1/HAI-2 inhibitor observations in a cellular setting, we conducted
peptidolytic activity assays utilizing whole cell extracts of cells expressing untagged TMPRSS13
either alone or together with HAI-1 or HAI-2 (Fig. 10B). No significant inhibition of activity, as
measured by decreased absorbance compared to lysates of cells expressing WT-TMPRSS13
alone, was observed upon TMPRSS13/HAI-1 co-expression, whereas significant TMPRSS13
inhibition was seen when co-expressed with HAI-2.

As expected, no substrate conversion

above mock background levels was observed when HAI-1 or HAI-2 was expressed without
TMPRSS13, or when catalytically inactive S506A-TMPRSS13 was expressed. Taken together,

58

Figure 10: HAI-1 and HAI-2 mediate TMPRSS13
phosphorylation.
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Figure 10. (A) Recombinant protease (5 nM) from Pichia pastoris clones transfected with either
TMPRSS13 (black bars) or matriptase (white bars) was incubated at 37 °C for 60 min with the
synthetic chromogenic peptide Suc-Ala-Ala-Pro-Arg-pNA (100 μm) in the absence or presence
of the inhibitor indicated (inhibitor and substrate added concomitantly). The absorbance at 405
nm was recorded and enzyme activities for each enzyme are depicted relative to activity when
no inhibitor was added. Asterisks indicate significant inhibition (ANOVA multiple comparisons: p
< 0.0001) compared to “no inhibitor” measurements. (B) 200 μg of whole cell protein lysates
from HEK293T cells transfected with the plasmids indicated were incubated with the
chromogenic peptide Suc-Ala-Ala-Pro-Arg-pNA (100 μm) at 37 °C for 60 min and absorbance at
405 nm was recorded. Asterisks indicate significant decrease in proteolytic activity compared to
WT-TMPRSS13+EV measurement (ANOVA multiple comparisons (p < 0.01)). n.s. = no
significance. (C) Lysates from HEK293T cells that were transiently transfected with full-length
human HAI-1 alone, HAI-2 alone, or together with WT-TMPRSS13 or either empty vector (EV),
were separated by SDS-PAGE and analyzed by Western blotting. (D) Protein lysates (5 µg)
from cells expressing WT-TMPRSS13-V5 with HAI-2 were treated with CIP for 60 minutes at
37ºC and analyzed by Western blotting under reducing conditions. WT-13-V5 = WTTMPRSS13-V5. (E) Cells expressing empty vector (EV), WT-TMPRSS13-V5/EV, HAI-1/EV,
HAI-2/EV or WT-TMPRSS13-V5 with either HAI-1 or HAI-2 were immunoprecipitated with α-V5
antibody and analyzed by Western blotting (right panels). Whole cell lysates were analyzed by
Western to verify expression before precipitation (input) (left panels). (F) Conditioned media
from HEK293T cells expressing the indicated proteins were collected 24 hours after addition of
serum free media and analyzed by Western blotting under reducing conditions.
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these data are in concordance with the results from cell-free assays above (Fig. 10A) and
further indicate that HAI-2 is a more efficient inhibitor of TMPRSS13 proteolytic activity than
HAI-1.
To determine whether there is a functional link between TMPRSS13 activation,
phosphorylation, and HAI, lysates from HEK293T cells co-expressing either HAI-1 or HAI-2, and
WT-TMPRSS13 were analyzed by Western blotting (Fig. 10C). Co-expression of HAI-2 and WTTMPRSS13 resulted in the appearance of a HMW species that corresponds in size to the
phosphorylated form of TMPRSS13. This species was verified to be phosphorylated
TMPRSS13 by CIP treatment, which led to the expected shift in mobility (Fig. 10D).

Co-

expression of WT-TMPRSS13 with HAI-1 resulted in no or weak signal of the phosphorylated
TMPRSS13 species in whole cell lysates by Western blotting (Fig. 10C). We suspected this
could, at least in part, be due to limited detection capability of the α-extra-TMPRSS13 antibody,
since a signal was detected in whole cell lysates of cells expressing WT-TMPRSS13-V5 and
HAI-1 at longer exposure (Fig. 10E, input, and Fig. 12A, whole lysate). When WT-TMPRSS13V5 was immunoprecipitated from lysates of cells co-expressing either HAI-1 or HAI-2,
phosphorylated TMPRSS13-V5 was detected in both samples, albeit at lower relative levels for
HAI-1 (Fig. 10E, IP:V5), indicating that both HAI-1 and HAI-2 lead to increased TMPRSS13
phosphorylation. Additionally, the co-immunoprecipitation of TMPRSS13-V5 with HAI-1 and
HAI-2, respectively, indicates association between each of the inhibitors and TMPRSS13 (Fig.
10E). Taken together, these data indicate that co-expression of HAI-1 or HAI-2 with TMPRSS13
promotes TMPRSS13 phosphorylation.
We consistently observed lower levels of both total and phosphorylated TMPRSS13
when expressed with HAI-1 compared to HAI-2 (Fig. 10C and 10E), which could be due to
enhanced activation and shedding of TMPRSS13 from the cell surface when co-expressed with
HAI-1. Conditioned media analyzed from cells co-expressing untagged WT-TMPRSS13 with
either HAI-1 or HAI-2 revealed that co-expression of TMPRSS13 with either inhibitor results in
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increased shedding of the TMPRSS13 active SP-domain into the media compared to WTTMPRSS13 without HAI expression (Fig. 10F). A greater relative amount of the shed SPdomain is observed upon HAI-1 co-expression compared to HAI-2 co-expression alongside
TMPRSS13. Similar observations were previously described for the TTSP family member,
matriptase. When matriptase was co-expressed with either HAI-1 or HAI-2, more shed
matriptase was detected in the presence of HAI-1 in MDCK cells (124). These data suggest that
the lower levels of the phosphorylated TMPRSS13 observed in cells co-expressing HAI-1
compared with HAI-2 may have resulted from increased activation and shedding of TMPRSS13
due to lower inhibitory potential of HAI-1 towards TMPRSS13 compared to HAI-2 (Figs. 10A-B,
F).
To further study the role of HAI-1 and HAI-2 in regulating cell surface localization of
TMPRSS13, HEK293T cells were co-transfected with WT-TMPRSS13-V5 and either empty
vector, HAI-1, or HAI-2, followed by immunocytochemical analysis (Fig. 11). Visualization of
HAI-1 was accomplished using the M19 antibody (125) and HAI-2 was visualized using a vector
expressing a HAI-2-EYFP fusion protein (124). As expected, transfection with WT-TMPRSS13V5 alone resulted in intracellular, perinuclear accumulation of the protease (Fig. 11A).

In

contrast, co-expression with HAI-1, which itself mainly localizes to the cell surface, led to cellsurface localization of TMPRSS13 as well as some intracellular staining (Fig.11B). In cells coexpressing HAI-2-EYFP and WT-TMPRSS13-V5, HAI-2 localizes mostly intracellularly (Fig.
11C), in accordance with previous observations in MDCK cells (124). TMPRSS13 appears to
co-localize with HAI-2 intracellularly as well as at the cell surface (also refer to the surface
biotinylation data below). It is plausible that interactions between TMPRSS13 and HAI-2 take
place along the secretory pathway since co-localization of HAI-2 with endoplasmic reticulum
and cis-Golgi markers has been previously reported (124,150).
To verify that TMPRSS13 is localizing to the cell surface, and to identify which form(s) of
TMPRSS13 is(are) surface-associated, we performed biotin-labeling of cell surface proteins on
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Figure 11: HAI-1 and HAI-2 mediate TMPRSS13 cell-surface
localization

Figure 11. Permeabilized cells transfected with WT-TMPRSS13-V5 alone (A) or co-transfected
with HAI-1 (B), or HAI-2-EYFP (C) were stained with anti-V5 (A and C), or anti-V5 and the antiHAI-1 M19 antibody (B). The cells were visualized by confocal fluorescence microscopy. Nuclei
(DAPI) (blue, A, B, C), WT-TMPRSS13-V5 (red, A, B, C), HAI-1 (green, B), and HAI-2-EYFP
(green, C). Merged images are shown in panels on the right.

63

Figure 12: Localization of phosphorylated TMPRSS13 on the
cell surface

Figure 12. Cell surface proteins of HEK293T cells expressing WT-TMPRSS13-V5 or HA-WTTMPRSS13 (C) with either empty vector (EV) (A, left), HAI-1 (A, right), or HAI-2 (B) were biotin
labeled at room temperature for 30 minutes. Biotin-labeled proteins were precipitated with
streptavidin agarose for 60 minutes at 4ºC. Streptavidin-agarose beads were then pelleted and
the supernatant containing proteins that were not precipitated with streptavidin agarose were
collected (wash). Biotin-labeled proteins were eluted from beads by treatment with Laemmli
sample buffer with 5% 2-Mercaptoethanol and run side-by-side with non-labeled proteins and
whole lysates prior to streptavidin treatment. Different exposures for V5 Western blot
membranes are displayed.
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intact HEK293T cells expressing WT-TMPRSS13-V5 with either empty vector, HAI-1, or HAI-2
(Fig. 12A and 12B). As expected, when WT-TMPRSS13-V5 was expressed without HAI-1 or
HAI-2, no or very low levels of cell-surface biotin-labeled protease were detected by Western
blotting (Fig. 8A, left) in accordance with the immunocytochemistry data in figures 5A and 11A.
In contrast, co-expression with HAI-1 or HAI-2 resulted in surface-associated TMPRSS13 (Figs.
12A, right and 12B). Interestingly, the V5-tagged phosphorylated, full-length inactive (~95 kDa)
and active protease (~38 kDa) SP-domain species appeared to be predominantly localized at
the cell surface, since those TMPRSS13 species were readily detected in the biotin labeled
samples, and little to no phosphorylated or active TMPRSS13 was observed in the
corresponding,

non-biotinylated

fractions

(wash

lanes).

Correspondingly,

the

non-

phosphorylated, full-length inactive TMPRSS13 species (~75 kDa) was detected in the wash
lanes (Fig. 12A and 12B). This experiment was repeated with co-transfection of N-terminal HAtagged (HA-WT-TMPRSS13) and HAI-2 with similar results (Fig. 12C). According to these data,
the non-phosphorylated, inactive full-length species localizes primarily intracellularly. Notably,
cells expressing TMPRSS13 with HAI-1 display the highest active SP-domain to total
TMPRSS13 ratio comparatively to TMPRSS13 with HAI-2 on the cell surface. It is possible that
this could, at least in part, be attributed to the poor inhibitory capability of HAI-1 towards
TMPRSS13, which may lead to increased auto-activation of TMPRSS13. Importantly, both HAI1 and HAI-2 are detected in the biotinylated samples indicating that they both localize to the cell
surface. Collectively, these data indicate that HAI-1 and HAI-2 promote TMPRSS13
phosphorylation and cell surface localization of the protease, and that phosphorylated
TMPRSS13 is the predominant form present at the cell surface.
3.3 Biochemical Characterization Discussion
As an effort to characterize the hepsin/TMPRSS subfamily member, TMPRSS13, we
performed biochemical and cell biological analyses. Expression of human, full-length
TMPRSS13 cDNA in mammalian cells led to the production of a recombinant glycoprotein that
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could be detected in both cell lysates and as a shed form in conditioned media. Full-length
TMPRSS13 displayed proteolytic activity both in whole cell extracts and in conditioned media.
Like various other TTSPs, including matriptase, matriptase-2, hepsin, TMPRSS2, TMPRSS3,
and TMPRSS4 that are capable of auto-activation (36), the proteolytic activity of TMPRSS13
also appears to be involved in its own activation. Mutation of the active site serine residue led
to decreased levels of detectable active SP-domain by Western blotting. Addition of active,
recombinant TMPRSS13 to cell surface catalytically deficient TMPRSS13 (S506A-TMPRSS13V5) also led to TMPRSS13 two-chain conversion. Intriguingly, the well-studied TTSP family
member, matriptase, is also capable of cleaving TMPRSS13 at its activation site. Therefore,
matriptase may function as an activator of TMPRSS13 in certain conditions; however the
physiological relevance of this phenomenon awaits further study.
Cell imaging studies revealed that catalytic inactivation of TMPRSS13 by either mutation
of the catalytic serine, or of the arginine residue in the zymogen activation site, results in
efficient cell surface localization of TMPRSS13. WT-TMPRSS13 failed to localize at the cell
surface and was largely detected intracellularly. However, when TMPRSS13 is expressed with
either

HAI-1

or

HAI-2,

efficient

cell

surface

localization

is

observed

using

both

immunocytochemistry and cell surface protein biotinylation assays. Therefore, the cognate
inhibitors HAI-1 and HAI-2 may facilitate TMPRSS13 localization by preventing aberrant
intracellular activation. In this regard, it is interesting to note that HAI-1 displays weak inhibitory
activity towards TMPRSS13. Previous reports examining the transport of the TTSP family
member matriptase to the cell surface have proposed that HAI-1 interacts with the zymogen
form of matriptase, thus preventing intracellular activation and to aid in its transport to the cell
surface (124,146,147,151). Therefore HAI-1 may function in a similar manner by interacting with
the zymogen form of TMPRSS13 to prevent artificial intracellular activation of TMPRSS13.
One of the most intriguing findings of our studies is the presence of a phosphorylated
form of TMPRSS13. To our knowledge, this is the first time a TTSP, or any other membrane
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serine protease, has been demonstrated to be modified by phosphorylation. Biotinylation
studies revealed that the phosphorylated species primarily localizes at the cell surface,
presenting the possibility that phosphorylation of TMPRSS13 promotes its translocation to the
cell surface. Additionally, in the experiments designed to determine whether TMPRSS13 is
capable of auto-activation, the full-length phosphorylated species is the predominate species to
be converted into the two-chain form. The mechanism of TTSP auto-activation is not known,
however it is thought to involve oligomerization (36). Therefore, one possibility is that
phosphorylation of TMPRSS13 promotes oligomerization and cleavage into the two-chain
species, thus linking phosphorylation events to zymogen conversion of TMPRSS13. Indeed,
previous reports on proteins that contain IDR’s have demonstrated that phosphorylation of
disordered regions allows for tight control over protein-protein interactions (152,153). Additional
studies are needed to gain a better understanding of the consequences of TMPRSS13
phosphorylation.
Previous studies of protease phosphorylation mainly focused on intracellular proteases
including caspases and deubiquitinating enzymes (DUBs) (154). ADAM (A Disintegrin And
Metalloproteinase) proteases have also been shown to be phosphorylated (155). The C-terminal
domain of the transmembrane ADAM17 undergoes phosphorylation at different sites including
Thr735 and Ser819 and phosphorylation at Thr735 was found to be necessary for ADAM17catalysed shedding of TGF-alpha. With ADAM15, phosphorylation of the cytoplasmic domain
resulted in interaction with several potential signaling proteins, including the Src kinases, Hck
and Lek (156). It is plausible that phosphorylation of TMPRSS13 regulates similar and/or
additional processes including localization, protein-protein interactions, and activation.
Currently, the kinases responsible for TMPRSSS13 phosphorylation are unknown.
Phosphorylation software tools predict potential candidates for multiple serine residues within
the intracellular domain, including the stress activated kinases JNK and p38MAPK, the cyclin
dependent kinases (CDK) 2 and 5, and ERK1. Other candidates have been suggested including
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CaM kinase II and protein kinase C (128,129). Future studies to identify the kinase(s)
responsible for TMPRSS13 phosphorylation may reveal novel insights into the cellular pathways
in which TMPRSS13 is involved.
TMPRSS13, HAI-1, and HAI-2 are co-expressed in many developing and adult
mammalian epithelia including simple, transitional, and multi-layered squamous epithelia
(65,149,157). The current study provides novel information about the regulation of TMPRSS13
activity, HAI-mediated cell surface localization, and phosphorylation, and may represent a new
post-translational mechanism critical for cellular regulation and function of TMPRSS13 and
other, similar proteases.
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CHAPTER 4: TMPRSS13 IN BREAST CANCER
4.1 Materials and methods
4.1.1 Animals
All procedures involving live animals were performed in an Association for Assessment
and Accreditation of Laboratory Animal Care International-accredited vivarium following
institutional guidelines and standard operating procedures. Tmprss13 deficient mice
(Tmprss13tm1Dgen) were generated by Deltagen Inc. and acquired from Jackson Laboratories
(Bar Harbor, ME). The mice were generated by homologous gene recombination using a gene
targeting vector containing a promoterless LacZ-Neo fusion gene (β-galactosidase reporter) in
129P2 OlaHsd-derived E14 embryonic stem cells. Recombination resulted in an in-frame
insertion and deletion of exon 10 and 92 bp of exon 9 encoding the Asp residue of the catalytic
triad. Expression results in a fusion protein consisting of the first 377 amino acids of TMPRSS13
fused to β-galactosidase (65). Genotyping was performed using the following primer sets for
Tmprss13:

moIMR0012

(5’-GGGTGGGATTAGATAAATGCCTGCTCT-3’),
and

AAATGACCCACCTAATTAGCTGTAG-3’),

oIMR6316

oIMR6318

(5’(5’-

GCCTCAATGAGACCTGTTGGATCAC-3’).
Mice transgenic for the MMTV-Polyoma virus middle T oncogene (PyVT) in the FVB/N
background (strain: FVB/N-Tg (MMTV-PyVT)634Mul) were obtained from The Jackson
Laboratory and crossed with Tmprss13-/- mice to generate F1 PyVT/Tmprss13+/- mice. Male F1
PyVT/Tmprss13+/- mice were then crossed with Tmprss13-/- mice to generate F2 study cohorts
of PyVT/Tmprss13+/- (hereafter referred as PymT/Tmprss13-control mice) and PyVT/Tmprss13-/(hereafter referred as PymT/Tmprss13-/- mice) female littermates. Genotyping for the PymT
allele

was

performed

with

the

CGGCGGAGCGAGGAACTGAGGAGAG-3’),
TCAGAAGACTCGGCAGTCTTAGGCG-3’)

following
and

primer

sets:
PymT

PymT
down:

up:

(5’(5’-
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4.1.2 Western blotting
Cultured human cells were lysed using RIPA buffer: 50 mM, Tris, 150 mM, NaCl, 0.1%
SDS, 0.5% deoxycholic-acid, 1% NP-40, pH 7.4 supplemented with protease inhibitor cocktail
(Sigma-Aldrich, St. Louis, MO) and cleared by centrifugation at 12,000 x g at 4ºC. Protein
concentrations were determined using a Pierce BCA Protein Assay Kit (Thermo Scientific,
Waltham, MA). Lysates were separated under reducing conditions on 10% SDS-page gels and
blotted onto PVDF membranes. Breast cancer lysates for cell line expression panel were a kind
gift from Dr. Julie Boerner (Karmanos Cancer Institute, Detroit M). Antibodies used in western
blot detection were: rabbit anti-TMPRSS13 (ab59862 – Abcam, Cambridge, MA), rabbit antiPARP (9532S – Cell Signaling Technologies, Danvers, MA), rabbit anti-Bcl-xL (2764 – Cell
Signaling Technologies, Danvers, MA), and mouse anti-beta-actin (Sigma St. Louis, MO).
Secondary antibodies were goat anti-rabbit or goat anti-mouse HRP-linked (Millipore, Billerica,
MA). For detection, secondary antibodies conjugated with horseradish peroxidase (Chemicon,
Temecula, CA) in combination with Super-SignalWest Femto or ECL Chemiluminescent
Substrate (Pierce, Rockford, IL) were used.
4.1.3 Cell culture of human breast cancer cell lines
MCF7 cells were cultured in Dulbecco’s modified Eagle’s media (DMEM) (Gibco, Life
Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum (Atlanta
Biologicals, Lawrenceville, GA). BT-20 cells were grown in Eagles + NEAA media (Eagle’s
MEM with 2 mM L-glutamine and Earle’s BSS adjusted to contain 1.5g/L sodium bicarbonate,
0.1 mM non-essential amino acids, 1mM sodium pyruvate, and 10% FBS). HCC1937 cells were
grown in RPMI + L-GLUT media (RPMI-1640 media with 2 mM L-glutamine adjusted to contain
1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, 1 mM sodium pyruvate, and 10%
FBS).

Transient

knockdown

of

TMPRSS13

expression

was

performed

using

Lipofectamine® RNAiMAX according to the manufacturer’s instructions (Invitrogen, Life
Technologies, Grand Island, NY). Stealth siRNATM constructs were obtained from Invitrogen life
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technologies (HSS130532 [corresponding to siRNA-32], and HSS130531 [corresponding to
siRNA-31]).
4.1.4 X-gal staining of mouse tissue
Resected mouse tissue was stained with BetaBlue reaction Millipore Burlington, MA)
buffer overnight at 37ºC. Tissues were then fixed for 24 hours in 10% neutral-buffered zinc
formalin (Z-fix, Anatech, Battle Creek, MI), processed and embedded into paraffin and
sectioned.
4.1.5 Immunohistochemistry analyses of mouse tissue
Tissues were fixed for 24 hours in 10% neutral-buffered zinc formalin (Z-fix, Anatech,
Battle Creek, MI), processed into paraffin and sectioned. Antigens were retrieved by heating in
epitope retrieval buffer-reduced pH (Bethyl Laboratories, Montgomery, TX). The sections were
blocked for 1 hour at room temperature with 2.5% normal horse serum in PBS prior to
incubation overnight at 4°C with primary antibody. Primary antibodies used were rabbit antimatriptase (1:100) and goat anti-c-Met (1:100)(R&D Systems, Minneapolis, MN). Cell
proliferation was visualized by intraperitoneal injection of 100 μg/g bromodeoxyuridine (BrdU)
(Sigma Chemical Co, St. Louis, MO) 2 h before euthanasia. BrdU incorporation was detected
with a rat anti-BrdU antibody (Accurate Chemical and Scientific Corporation, Westbury, NY,
1:10). Macrophages were detected by a rat anti-F4/80 antibody (1:50) (Invitrogen, Life
Technologies, Grand Island, NY). As negative controls for macrophage staining, IHC samples
were treated with biotinylated anti-rat IgG (Vector Laboratories Burlingame, CA) and labeled
with vectastain ABC Kit (Vector laboratories Burlingame, CA). Apoptotic cells were detected
with rat anti-cleaved caspase-3 (Cell Signaling Technologies, Danvers, MA). Negative controls
were treated with non-immune rabbit IgG(adjusted to same final concentration as specific
primary antibodies). Primary antibody labeling was then performed using ImmPRESS Reagent
Kit anti-rabbit Ig kit (Vector laboratories Burlingame, CA). All staining was performed with
SIGMAFAST™ 3,3′-Diaminobenzidine tablets (Sigma-Aldrich St. Louis, MO).

71
4.1.6 Breast cancer tissue array
The use of human tissue paraffin embedded samples was approved according to the
Institutional Review Board Administration. The “BR723 and T088A” breast cancer tissue arrays
with pathology grading were obtained from US Biomax, Inc. (Rockville, MD). Tissue arrays were
deparaffinized with xylene and hydrated with graded ethanol solutions. Antigen retrieval was
performed using heated citrate buffer, reduced pH (Bethyl Laboratories, Montgomery, TX). The
arrays were blocked with 2 % bovine serum albumin in PBS, and immunostained overnight at
4°C5. Primary antibodies were rabbit anti-TMPRSS13 (PA5-30935 1:250) (Thermo Scientific,
Waltham, MA). As negative control rabbit IgG was used (Sigma, St. Louis, MO) (adjusted to
same final concentration as specific primary antibodies). Primary antibody labeling was then
performed using ImmPRESS Reagent Kit anti-rabbit Ig kit (Vector laboratories Burlingame, CA).
All staining was performed with SIGMAFAST™ 3,3′-Diaminobenzidine tablets (Sigma-Aldrich St.
Louis, MO).
4.1.7 Proliferation assays in human breast cancer cell lines
Breast cancer cell lines were seeded in 12-well plates at 50,000 cells/well. Simultaneous
reverse transfection with siRNA targeting TMPRSS13, or GC-matched control, was performed
upon seeding using RNAiMAX according to the manufacturer’s instructions (Invitrogen, Life
Technologies, Grand Island, NY). Cells were counted using a hemocytometer at the indicated
days post knockdown and adjusted to number of cells originally seeded. Necrotic cells were
labeled with 0.4% trypan blue stain (Life Techonologies (Grand Island, NY) prior to counting.
4.1.8 Invasion assays
Cells were first seeded in 6-well plates while performing simultaneous reverse
transfection with either siRNA targeting TMPRSS13 or GC-matched control using RNAiMAX
according to the manufacturer’s instructions (Invitrogen, Life Technologies, Grand Island, NY).
Fourty-eight hours post silencing, cells were seeded in 8.0uM pore size chambers (Corning
Corning, NY) pre-treated with MatrigelTM matrix at 1mG/mL concentration in reduced serum
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media. Full-serum media was placed underneath chambers to act as chemoattractant. Cells
were allowed to invade overnight and the number of cells that had invaded were stained with
Diff-Quik Stain Set (Siemens Newark, DE) per manufacturer’s protocol and counted using
ImageJ software.
4.1.9 Cell viability assays
Cells were first seeded in 6-well plates while performing simultaneous reverse
transfection with either siRNA targeting TMPRSS13 or GC-matched control using RNAiMAX
according to the manufacturer’s instructions (Invitrogen, Life Technologies, Grand Island, NY).
Forty-eight hours post silencing cells were counted and 12,000 cells/well were added to 96-well
black, clear bottom plates (Corning Corning, NY). Twenty-four hours post seeding cells were
treated with vehicle control or Paclitaxel (T7402 - Sigma-Aldrich St. Louis, MO). Forty-eight
hours after treatment cell viability was analyzed Calcein AM Cell Viability Assay per
manufacturers protocol (Trevigen Gaithersburg, MD)
4.2 TMPRSS13 in breast cancer - Introduction
Breast cancer progression is accompanied by increased expression of extracellular and
cell-surface proteases that are capable of degrading the extracellular matrix as well as cleaving
and activating downstream targets. Traditionally, proteolytic processes were thought to
exclusively be involved in modifying the tissue microenvironment within the breast to allow for
cancer cell invasion and dissemination to other organs. However, more recently, proteases
have gained attention for also playing a role in the promotion of cancer progression via the
regulation of pro-oncogenic signaling pathways. These proteolytic pathways have been shown
to be significantly involved in the relationship between the proliferating tumor and its
surrounding stroma to mediate various aspects of tumor progression including proliferation,
angiogenesis, inflammation, and survival (2,158,159).
The vast majority of studied proteases involved in cancer progression are secreted
proteases expressed in the stroma of breast tumors by fibroblasts or inflammatory cells.
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However, a new protease family of 17 structurally unique multi-domain serine proteases that are
anchored directly to the plasma membrane, termed the type II transmembrane serine proteases
(TTSPs), was discovered at the turn of the millennium (36). Since their discovery, this family of
proteases has been shown to play critical and essential roles in normal development, tissue
homeostasis, and disease, including cancer (126,160). The expression of TTSP’s in cancer is
often dysregulated, and various TTSP’s, cancer including matriptase, hepsin, TMPRSS2, and
TMPRSS4, have been shown to play important tumor promoting roles (159).
To identify novel TTSP family members that may play a role in breast cancer
progression, we performed a systematic screening of the expression profiles of TTSP family
members in both normal and invasive ductal carcinoma (IDC) patient samples. A candidate
family member known as Transmembrane Protease, Serine 13 (TMPRSS13) showed
significantly increased mRNA expression in IDC compared to normal breast tissue. Currently,
no published study has examined the expression or function of TMPRSS13 in cancer. Several
studies have been published indicating a role for TMPRSS13 in influenza infection due to its
ability to proteolytically modify the viral protein hemagglutinin, thereby mediating membrane
fusion of the pathogenic avian influenza viruses (130,131). Additionally, a physiological role has
been implicated for TMPRSS13 through characterization of TMRPSS13-deficient mice, which
display a defect in skin development with impaired epidermal barrier acquisition (65). Several
biochemical studies have also been published on TMPRSS13, one of which demonstrated that
the serine protease domain of TMPRSS13 is capable of activating the pro-oncogenic signaling
molecule hepatocyte growth factor (HGF) in vitro (66), and it is currently the only known TTSP
family member to be phosphorylated, which may play a role in its cell surface localization (40).
In the current study, in vivo “loss-of-function” strategies using novel genetic mouse
models along with complementary human cell culture models were performed to determine
whether TMPRSS13 plays a role in breast cancer. We demonstrate here that TMPRSS13
expression is increased in both human and murine breast cancer, and that genetic ablation of
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TMPRSS13 impairs mammary cancer progression resulting from decreased proliferation and
increased apoptosis in vivo. Additionally, we demonstrate that loss of TMPRSS13 in human
triple negative breast cancer (TNBC) cell lines increases chemosensitivity to paclitaxel
treatment, suggesting a pro-survival role of TMPRSS13 in breast cancer.
4.3 TMPRSS13 in breast cancer - Results
4.3.1 Increased expression of TMPRSS13 in breast cancer
As part of ongoing efforts to determine the expression and function of the type-II
transmembrane serine protease (TTSP) family members in breast cancer, a systematic
expression analysis using the OncomineTM database was performed. The in sillico analysis
revealed that TMPRSS13 transcript levels are significantly increased in invasive ductal
carcinoma (IDC) patient samples compared to normal breast tissue using The Cancer Genome
Atlas (TCGA) dataset (Fig. 13A). To verify the increased expression at the protein level a panel
of breast epithelial cell lines were screened for expression by Western blotting, and patient
tumor samples were stained for TMPRSS13 expression by immunohistochemistry (IHC).
Western blotting results demonstrate that TMPRSS13 has increased expression in several
breast cancer cell lines of a diverse origin compared to the non-malignant breast epithelial cell
lines, MCF10a and hTERT-HME1, which show little to no expression of TMPRSS13 (Fig. 13B).
IHC analysis of TMPRSS13 expression from 24 patient samples displayed an increase in
TMPRSS13 protein expression in the IDC samples compared to the normal and benign breast
lesions (Fig.13D). Additionally, TMPRSS13 expression is specifically localized to the malignant
epithelial cells and not the surrounding stroma, whereas little to no detection of TMPRSS13 is
observed in the non-malignant samples (Fig. 13C). Taken together these data indicate that
TMPRSS13 expression is increased in breast cancer at both the transcript and protein levels.
4.3.2 Increased TMPRSS13 expression in the MMTV-PymT model of breast cancer
To examine the effects of TMPRSS13 on breast cancer progression in vivo, the mouse
mammary tumor virus (MMTV) Polyoma middle T (PymT) transgenic mammary tumor model

75

Figure 13: TMPRSS13 expression in breast cancer

Fig. 13. (A) Box and whisker plot representing TMPRSS13 mRNA expression data for normal
breast (N=60, median= -0.8) and IDC (N=468, median= 0.3) from the OncomineTM microarray
database (TCGA data). Boxes show interquartile range, and medians are indicated by
horizontal lines (B) Elevated TMPRSS13 expression in seven breast cancer lines compared to
two non-malignant breast epithelial lines assessed by Western blotting. (C) IHC analysis of
human patient samples reveals very low to no detectable TMPRSS13 in normal mammary
glands (duct indicated with arrow) and pronounced TMPRSS13 staining in carcinoma cells
(brown) with no detectable expression in the stroma (yellow asterisk). (D) Staining intensity was
assessed using defined scoring criteria by two different investigators unaware of sample
identity. Dots represent samples from individual patients. Significant differences are observed
between normal versus IDC (P<0.05) and benign (adenosis and fibroadenoma) versus IDC
(P<0.05). Blue horizontal line=median.
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was utilized. These transgenic mice express the Polyoma middle-T antigen under the
transcriptional control of the mouse mammary tumor virus promoter, thus resulting in the
expression of the PymT oncoprotein in mammary epithelial cells. Due to the expression of the
PymT oncoprotein in mammary epithelial cells, mice develop mammary tumors approximately 1
to 6 months after birth (50). Furthermore, the MMTV-PymT model of breast cancer is further
characterized by having a 100 percent penetrance of primary tumors, with a high occurrence of
lung metastasis, and closely resembles the progression of human breast cancer. (161-163)
In order to ensure that the MMTV-PymT mouse mammary cancer model mimics the
observations described above in human breast cancer and the normal breast, we assessed the
expression and localization of murine TMPRSS13 protein. We took advantage of the
promoterless β-galactosidase reporter gene cassette being under the transcriptional control of
the endogenous Tmprss13 promoter in TMPRSS13+/- mice. Therefore, X-gal staining of tissue
followed by whole mount or histological examination allows for precise detection of TMPRSS13
expression in mouse tissue. Glands from heterozygous TMPRSS13+/- mice with or without the
MMTV-PymT transgene were examined and revealed that TMPRSS13 expression is not
detected in the normal mammary gland (Fig. 14C), whereas it is readily detected in mammary
carcinomas (Figs. 14A and D). Additionally, the expression of TMPRSS13 is specifically
expressed in the malignant epithelial cells and not the surrounding stroma, corresponding to the
expression pattern observed in human patient samples (Figs. 13C and 14D). Furthermore,
whole mount staining of resected lungs from 170-day old mice reveals that TMPRSS13 is also
expressed at the metastatic lung lesions (Fig. 14B).
4.3.3 TMPRSS13 deficiency delays tumor development and decreases tumor burden,
growth rate, and metastasis in vivo
To test the effects of genetic ablation of TMPRSS13 in vivo on breast cancer
progression, comparative analyses were performed on TMPRSS13-deficient and control mice
harboring the MMTV-PymT transgene. Prospective littermate cohorts were established by
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Figure 14: TMPRSS13 is expressed in cancer cells of murine
mammary carcinomas

Fig. 14. Endogenous TMPRSS13 visualized by X-gal staining (blue). (A) TMPRSS13 is
expressed in MMTV-PymT mammary carcinomas (arrows) and (B) in lung lesions (arrows) in
whole mounts. (C-D) Histological analysis: no detectable TMPRSS13 in normal mammary ducts
(arrow in C) (C) whereas TMPRSS13 is readily detected (blue, arrows in D) in carcinoma cells
in tumors from MMTV-PymT transgenic mice (D). No detectable expression of TMPRSS13 in
the stroma (asterisk). LN=lymph node. You probably need to include tumor WT without blue too
as E.
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crossing TMPRSS13+/-/MMTV-PymT with TMPRSS13-/- mice to generate TMPRSS13deficient/MMTV-PymT and control mice (TMPRSS13-/-/MMTV-PymT and TMPRSS13+/-/MMTVPymT respectively). Established littermate-controlled cohorts were monitored weekly for
detection of the first palpable mammary mass (tumor latency). A 129-day end-point was
established where total mammary tumor burden was assessed and calculated by the total
weight of the postmortem excised mammary glands of each individual mouse, and total tumor
area was calculated by caliper measurements. In addition, the presence of lung metastasis was
determined at the termination of the cohort experiment (day 129). TMPRSS13 deficiency
affected all tumorigenic parameters measured (Fig. 15). Thus genetic ablation of TMPRSS13
resulted in a significant delay in the formation of palpable mammary tumors in TMPRSS13deficient mice (Fig. 15A). Additionally, a significant decrease in the overall final tumor burden
was observed in TMPRSS13-deficient mice compared to control, with a 62% overall reduction in
the final tumor burden in TMPRSS13-/-/MMTV-PymT mice (median tumor burden of
TMPRSS13+/-/MMTV-PymT, 3.03 g, TMPRSS13-/-/MMTV-PymT, 1.16 g) (Fig. 15B). The growth
rate was also significantly reduced in TMPRSS13-deficient mice with a median growth rate of
1.53 mm2/day in TMPRSS13-deficient mice, compared to TMPRSS13 control mice that
displayed a growth rate of 2.67mm2/day (Fig. 15C). Furthermore, TMPRSS13-deficient mice had
a decreased incidence of lung metastasis (Fig. 15D) (P=0.052, Chi-square test). Taken together
these data indicate that TMPRSS13 deficiency impairs mammary cancer progression.
4.3.4 TMPRSS13 deficiency decreases tumor cell proliferation and increases apoptotic
cell death in vivo
TMPRSS13 deficiency results in a decreased final tumor burden and tumor growth rate
in vivo (Fig. 15B and C). To determine whether the decreased tumor growth in TMPRSS13 -/mice were due to either decreased proliferative abilities and/or increased programmed cell
death rates in TMPRSS13-/-/PymT tumors, tumor tissues were stained for either BrdU or the
cleaved form of caspase-3 as a marker for cells undergoing apoptosis. Adult 129-day old cohort
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Figure 15: Delayed tumor development, smaller tumors,
decreased growth rate and metastasis in TMPRSS13-/- mice

Fig. 15. (A) Kaplan-Meier plot of prospective cohort of littermate TMPRSS13+/MMTV-PymT
(N=15) and TMPRSS13-/-/MMTV-PymT mice (N=21). Mice were palpated weekly to detect time
of tumor formation. All control mice had palpable tumors at 84 days and TMPRSS13-/- mice at
127 days (P<0.001). (B) Tumor burden at 129 days. Mice were euthanized, mammary tumors
were resected and the total tumor weight was recorded. Median values; 3.03 g (control, N=14)
and 1.16 g (-/-, N=18) P<0.004. (C) Growth rate of mammary tumors in TMPRSS13+ (blue
circles) and TMPRSS13-/- (red circles) mice, P<0.05. (D) Presence of lung metastasis was
determined at the termination of the cohort experiment (day 129). Lung lesions were detected
using a dissection microscope and in H&E slides; Control mice 8/12 (67%) and TMPRSS-/- mice
4/14 (29%) P=0.052.

80
mice were injected with the BrdU nucleotide analog 2 hours prior to sacrifice. Tumors were then
removed, fixed and paraffin embedded, and histological staining was performed for BrdU
positive cells. TMPRSS13-/- mice displayed a decrease in proliferation with a 47% reduction in
the number of proliferating cells compared to control mice (Fig. 16A and B). TMPRSS13-/- mice
also displayed a marked increase in apoptotic cell death compared to the control littermate
mice, with a six-fold increase in the number of apoptotic cells in TMPRSS13-/- mice. (Fig. 16C
and D)
4.3.5 Silencing TMPRSS13 expression in human breast cancer cells decreases
proliferation and induces apoptosis
To test whether loss of TMPRSS13 effects cancer cell proliferation in human mammary
epithelial cells, TMPRSS13 expression was silenced in three separate breast cancer cell lines.
The BT20, HCC1937, and MCF-7 cell lines were chosen for these analyses because they, in
addition to expressing endogenous TMPRSS13, represent different breast cancer subtypes; the
highly invasive, TNBC, basal-like subtype (HCC1937 and BT20) and the poorly invasive, ER+,
PR+ Luminal A subtype (MCF-7). TMPRSS13 was silenced using two non-overlapping synthetic
RNA duplexes and scrambled GC-matched duplexes were used as controls. Cells were plated
in serum containing media, trypsinized, and counted on the days indicated (Fig. 17A). MCF-7
cells displayed a loss of cells at day 3 after TMPRSS13 silencing, indicative of cell death. In
HCC1937 and BT-20 significantly lower cell numbers were detected in TMPRSS13 silenced
cells (decrease in the slopes, siRNA vs. control). This indicates decreased proliferation and/or
cell survival. Taken together these data indicate that loss of TMPRSS13 expression reduces the
proliferation potential in breast cancer.
Loss of TMPRSS13 expression in the luminal like MCF7 breast cancer cell line results in
an overall decrease in cell numbers. To test whether the decrease in cell numbers is due to
increased apoptosis, lysates were collected at the indicated days for all three cell lines. The
levels of cleaved Poly (ADP-ribose) polymerase (PARP), a marker for apoptosis, in breast
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Figure 16: Decreased proliferation and increased apoptosis
in TMPRSS13-/- mice

Fig. 16 (A) Quantification of the number of BrdU positive proliferating cells in mammary tumors
from 129 day old TMPRSS13+/PymT (N=3) and TMPRSS13-/-/PymT (N=3) mice. Means:
TMPRSS13+ = 16.5% TMPRSS13-/- = 9.2% p<0.05 (B) Representative staining for the number
of BrdU positive cells in TMPRSS13+/PymT (left) and TMPRSS13-/-/PymT (right) mice. (C)
Quantification of the number of apoptotic cells in 129 day old TMPRSS13+/PymT (N=4) and
TMPRSS13-/-/PymT (N=4) mouse tumors. Means: TMPRSS13+ = 0.59% TMPRSS13-/- = 3.55%
p<0.05. Positive cells were counted by an investigator who was unaware of genotypes.
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Figure 17: TMPRSS13 silencing decreases human TNBC cell
proliferation and induces apoptosis

Fig. 17 (A) Relative mean cell numbers by hemocytometer counting following siRNA-mediated
knockdown of TMPRSS13 were assessed over time in serum containing media in three breast
cancer cell lines (MCF-7, BT20, and HCC1937). Each experimental condition was done in
triplicate. Error bars represent SD. Graphs are representative of three independent experiments.
Asterisks indicate significant difference from scrambled GC-matched control, *p <0.01.
**p<0.001,***p<0.0001. Black lines=control, red lines=TMPRSS13 knockdown. (B) Western blot
analysis of TMPRSS13, PARP and β-actin upon silencing with two different RNA duplexes
targeting TMPRSS13. (C) Western blot analysis of TMPRSS13, Bcl-xL, and β-actin upon
silencing with two different RNA duplexes targeting TMPRSS13 in HCC1937 cells (D)
Quantification of Bcl-xL protein normalized to β-actin.
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cancer cell lysates were detected by Western blot analysis. Loss of TMPRSS13 expression led
to increased PARP cleavage, in both the luminal like MCF7 and the TNBC cancer cell lines
BT20 and HCC1937 (Figs. 17B and 19D, right panel), indicative of enhanced apoptosis.
Additionally, Western blot analysis for the pro-survival marker BCL-xL in HCC1937 cells
revealed a decrease in expression (Fig. 17C and D), suggesting that loss of TMPRSS13 results
in decreased expression of pro-survival proteins.
4.3.6 TMPRSS13 deficiency reduces tumor cell invasive potential
TMPRSS13-/- mice display decreased incidence of metastatic lesions compared to
control mice. Therefore, we next analyzed whether TMPRSS13 may directly affect tumor cell
invasion potential – an important determinant for metastatic ability. The invasion potential of
breast cancer cells was studied using a transwell Matrigel® assay in which cells were seeded
on top of the matrix in serum free media and allowed to invade overnight towards serum
containing media in the bottom chamber (Fig. 18). Upon silencing of TMPRSS13 using two nonoverlapping synthetic RNA duplexes, a significant decrease in invasive potential was observed
in BT20 cells. Importantly, the experiment was carried out at day 2 after siRNA transfection
when no difference in cell number is observed between control and TMPRSS13 silenced cells
(Fig. 17A). This eliminates interference from differences in cell proliferation/survival with the
invasion assay results. Taken together, these data suggest that TMPRSS13 is critical for breast
cancer cell survival and invasion.
4.3.7 Loss of TMPRSS13 enhances chemosensitivity in triple negative breast cancer cell
lines
Silencing TMPRSS13 expression results in apoptotic cell death in human cell culture
models as well as reduced expression of the pro-survival marker Bcl-xL. Additionally, increased
spontaneous apoptotic cell death is observed in vivo. Taken together these data suggest that
TMPRSS13 may play a role in mediating tumor cell survival. TNBC is typically treated with a
combination of radiation therapy and chemotherapy; yet, patients with TNBC have a significantly
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Figure 18: TMPRSS13 silencing decreases human TNBC cell
proliferation and induces apoptosis

Fig. 18 Forty-eight hours post silencing, BT20 cells were serum starved in Transwell chambers
with polycarbonate filters coated with Matrigel®. Using serum containing media in the lower
chambers as chemoattractant, cells were allowed to invade through the matrix for 12 hours.
Cells that had invaded were stained with crystal violet and counted. Error bars=SD ,** P<0.01.
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lower 5-year survival than patients with other breast cancer subtypes. The major reason for low
response rates in TNBC patients is chemoresistance and there is an urgent need to identify new
targets that can be used as monotherapy or in combination therapy with established drugs. To
specifically explore expression of this protease in TNBC, we analyzed IDC data sets stratified
into TNBC versus non-TNBC (other hormone receptor status/hormone receptor positive). Two
representative data sets reveal significantly higher levels of TMPRSS13 in TNBC (red)
compared to receptor positive breast cancers (blue) (Fig. 19A). Thus, our data presented above
point to TMPRSS13 as a promising target in TNBC treatment.
To test whether TMPRSS13 promotes tumor survival under chemotherapeutic stress
conditions, preliminary experiments were performed to determine TMPRSS13-dependent
sensitivity to the chemotherapeutic agent paclitaxel. The two TNBC cancer cell lines BT20 (WT
PTEN and BRCA1 (164,165)) and HCC1937 (mutated PTEN and BRCA1 (164,165)) were
chosen to perform these experiments. Currently, taxanes (e.g. paclitaxel) are commonly used
as adjuvant and neoadjuvant therapies in TNBC patients (166). Taxanes are microtubule
targeting agents that prevent microtubule formation, resulting in cell cycle arrest. Additionally,
HCC1937 cells have been shown to be the most resistant to taxane and anthracycline treatment
since BRCA1 mutations are critical for chemotherapeutic sensitivity, and reconstitution of WTBRCA1 restores chemosensitivity to both taxanes and anthracycline resistance in HCC1937
cells (167).
The effects of silencing TMPRSS13 alone, drug treatment alone, or combination were
analyzed by both Western blot analysis of lysates from treated cells, and cell viability was
measured by Calcein AM treatment. Combination therapy results in a significant decrease in cell
viability compared to either treatment alone for both cell types (Fig. 19 B and C). Additionally,
analysis of lysates reveals increased amounts of PARP cleavage in combination treatment
compared to either treatment alone, indicative of increased apoptotic cell death (Fig. 19D).
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Figure 19: Increased chemosensitivity upon TMPRSS13
silencing in TNBC cell lines

Fig. 19 (A) Box and whisker plots representing TMPRSS13 mRNA expression data for (A) NonTNBC (N=250, median= -0.01) and TNBC (N=46, median= 0.9) (TCGA) and (B) Non-TNBC
(N=129, median= -0.9) and TNBC (N=39, median= 0.4)(Bittner) from the OncomineTM
microarray database. Boxes show interquartile range and medians are indicated by horizontal
lines. p<0.0001 for both A and B.. (B) BT-20 cells were treated with increasing concentrations
of paclitaxel in TMPRSS13 silenced cells or control cells treated with GC matched siRNA.
Percent decrease in viability was compared to no treatment control group for each cell type
(GC-matched control, siRNA1, siRNA2) (C) RNAi Knock-down (KD) cells or control cells were
treated with vehicle or 1 µM paclitaxel for 48h. Cell survival was measured using Calcein AM.
The combination treatment (purple bar) reduced cell survival by 91% compared to 31% with
paclitaxel alone (red bar). Negative control=no cells. Error bars=SD. **p<0.001. ***p<0.0001
compared to control/vehicle, ***p<0.0001, combination treatment compared to each monotreatment. (D) Corresponding lysates of BT-20 (treated with [100nM] paclitaxel or vehicle
control] or HCC1937 (treated with [100µM] paclitaxel or vehicle control) cells probed for
TMPRSS13, PARP, and beta-actin
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Taken together, these experiments indicate that loss of TMPRSS13 expression increases
chemosensitivity in breast cancer.
4.4 Discussion
In the current study, we report for the first time that TMPRSS13 expression is increased
in breast cancer, and that TMPRSS13 deficiency impairs breast cancer progression in vivo.
Additionally, loss of TMPRSS13 decreased proliferation and increased apoptotic cell death both
in human cell culture models and in tumors from the genetic MMTV-PymT model of breast
cancer. Furthermore, reduced number of lung metastasis is observed in TMPRSS13-/- mice
compared to control mice, and decreased invasion potential is observed upon TMPRSS13
silencing in the TNBC BT20 cell line. Together the data provides a comprehensive analysis of
the promotional role of TMPRSS13 in breast cancer.
To the best of our knowledge, this is the first study examining the biological role of
TMPRSS13 in cancer. A few other TTSP family members have been studied in breast cancer,
including both matriptase and hepsin, and both have been shown to promote tumor progression.
Matriptase was shown to be essential for the proteolytic conversion of pro-HGF into active HGF
to induce c-Met signaling and proliferation (81,168). Using both human cell culture models and
genetic in vivo models, it was demonstrated that reduced matriptase expression prevents
conversion of pro-HGF into active HGF, identifying pro-HGF as a physiological substrate for
matriptase in breast cancer and that matriptase is the primary pro-HGF activator in the models
used (which included the cells lines HCC1937 and BT20). Even though, TMPRSS13 has been
reported to cleave and activate pro-HGF in vitro, it is therefore unlikely that loss of TMPRSS13mediated activation critically impairs of pro-HGF activation and subsequent c-Met activation.
However, it cannot not be formally excluded that TMPRSS13 could contribute to pro-HGF
activation under conditions not tested in the previous (81,168) or present study. Additionally,
hepsin was shown to have increased expression levels in breast cancer, and that hepsin
overexpression in the non-transformed basal-like MCF10a cell line results in reduced
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expression of the desmosomal protein desmoglein 2, along with disruption of apical polarity and
cellular cohesion (98). The TTSP family member matriptase-2 has also been studied in breast
cancer, where lost expression of matriptase-2 expression occurs, and its re-expression results
in suppressed tumorigenic properties of breast cancer cells, suggesting tumor suppressive
functions of matriptase-2 in breast cancer (169). A previous study examining the TTSP family
member TMPRSS4 found that TMPRSS4 expression regulates the EMT transcription factor
slug in prostate cancer.
Interestingly, this study reports for the first time that loss of a TTSP family member
results in increased spontaneous apoptosis in cancer in vivo, as well as increased breast cancer
chemosensitivity. Therefore, this suggests that TMPRSS13 plays a pro-survival role in breast
cancer progression by promoting tumor cell survival and proliferation. The mechanism by which
TMPRSS13 exerts pro-survival effects is currently unknown and future studies examining
potential proteolytic substrates of TMPRSS13 may provide key insights. Additionally, TMPRS13
is currently the only TTSP family member known to be modified by phosphorylation, and that its
phosphorylation may result in its translocation to the cell surface (170). Kinase software
prediction tools have predicted that the c-jun n-terminal kinases, JNK1 and JNK2, may be
responsible for TMPRSS13 phosphorylation (170). During times of cellular stress various
signaling pathways are activated, and it is currently unknown whether TMPRSS13 is
phosphorylated during certain stress conditions. Therefore identifying the kinase(s) responsible
for TMPRSS13 phosphorylation, as well as the signaling pathways involved in TMPRSS13
phosphorylation may yield interesting insights into TMPRSS13 pro-survival mechanisms.
In conclusion, this study demonstrates that TMPRSS13 plays a promotional role in
breast cancer, and that loss of TMPRSS13 expression impairs breast cancer progression in
vivo. Additionally, we indicate that TMPRSS13 deficiency results in increased chemosensitivity,
suggesting that TMPRSS13 functions in a pro-survival manner during breast cancer progression
to support tumor growth.
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CHAPTER 5: FUTURE DIRECTIONS
The data above indicate that TMPRSS13 plays a pro-survival role in breast cancer,
however the mechanism by which it promotes cell survival remains unknown. During times of
cellular stress various signaling pathways are activated to either promote cell survival, or induce
cell death, depending on the duration and strength of the stress signaling (171,172). Therefore,
it is interesting to note that while characterizing TMPRSS13 it was revealed that TMPRSS13 is
phosphorylated, and that the stress activated protein kinases, Jun N-terminal kinase-1, -2 (JNK1
and JNK2), were predicted to be responsible for phosphorylation of TMPRSS13. JNK1 and
JNK2 are activated under various stress conditions, including oxidative stress (173). Therefore,
in preliminary experiments to test whether TMPRSS13 is phosphorylated under oxidative stress
conditions, MCF7 cells were treated with H2O2 or vehicle control and lysates were collected and
analyzed by Western blotting. Interestingly, TMPRSS13 appears to be phosphorylated in a time
dependent manner under H2O2 treatment (Fig. 20). The kinases directly responsible for
phosphorylating TMPRSS13 after H2O2 treatment remains unknown, and it is important to note
that other kinases, including JNK1 and JNK2, are activated under oxidative stress (173,174).
Therefore, future studies using RNAi, or inhibitors targeting specific kinases, will provide novel
insights into the kinases directly responsible for TMPRSS13 phosphorylation.
To further identify TMPRSS13 specific kinases, and to examine whether other types of
stimulation may induce TMPRSS13 phosphorylation, MCF7 cells were treated with the PKC
activator Phorbol 12-myristate 13-acetate (PMA). PMA and vehicle control treated cells were
lysed and protein extracts were collected at 15 minutes, 4 hours, or 16 hours after treatment.
Interestingly, no increase in TMPRSS13 phosphorylation was observed at any timepoint
compared to vehicle control group (data not shown). Therefore, this suggests that TMPRSS13
phosphorylation is not mediated by PKC, and that phosphorylation may be specific to increases
in reactive oxygen species (ROS) levels. Various stressors have been shown to increase ROS
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Figure 20: Oxidative stress induced phosphorylation of
TMPRSS13

Fig. 20 (A) MCF7 cells were treated with H2O2 (2mM) or vehicle control for the indicated times
and analyzed by Western blotting for the detection of the phosphorylated species. Western
analysis reveals that TMPRSS13 is increasingly phosphorylated under hydrogen peroxide
treatment over time.
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levels, including UV irradiation and chemotherapeutic stress (175,176), and future studies
examining the role of ROS levels in mediating TMPRSS13 phosphorylation may provide further
insights into TMPRSS13’s function in breast cancer. Additionally, the effect of phosphorylation
on TMPRSS13 is currently unknown, but it is speculated that it promotes its localization to the
cell surface (170). Therefore, it is interesting to speculate that under cellular stress, TMPRSS13
is phosphorylated resulting in TMPRSS13 translocation to the cell surface, however future
studies are needed to confirm this.
Future studies examining candidate proteolytic substrates of TMPRSS13 will provide
further key insights into the role of TMPRSS13 in breast cancer. Ongoing investigations into
identifying physiologically relevant substrates for TTSP family members is currently underway,
and only a handful of known substrates for a select few TTSP family members are known (159).
It has previously been reported that the TTSP family member matriptase is responsible for the
conversion of the oncogenic signaling molecule pro-HGF into active HGF to induce c-MET
signaling in breast cancer (168). However, currently no physiological substrates have been
validated for TMPRSS13. Therefore, future studies using both biased (in vitro co-incubation
studies), and unbiased proteomics approaches are being developed. Candidate substrates will
then be validated using both in vivo and cell culture models to assess whether decreased
proteolytic processing of candidate substrates is observed of upon loss of TMPRSS13
expression.
Additionally, the findings outlined above indicate that targeting TMPRSS13 in TNBC
cancer cell lines impairs cell survival/proliferation and invasion. Additionally, targeting
TMPRSS13 increases the sensitivity of breast cancer cells to chemotherapy. Based on these
findings, future studies to validate TMPRSS13 as a viable, druggable target in breast cancer
have been initiated. It is important to note that in characterizing TMPRSS13-/- mice, TMPRSS13
deficiency has no discernible consequences on adult mouse health (65), thereby indicating
limited adverse side effects would be observed with therapeutic TMPRSS13 inhibition. In early
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investigations into the development of TMPRSS13 specific small molecule inhibitors a
collaboration has been established with Drs. Leduc, Marsault and Richter at the Universitѐ De
Sherbrooke in Québec, Canada. After development of TMPRSS13 specific inhibitors, future
studies examining the effects of TMPRSS13 inhibition both alone, or in combination therapy
with established chemotherapeutics, will be performed.
Of the 17 TTSP family members, TMPRSS13 has been relatively uncharacterized in
both normal physiological development and disease. Characterization of TMPRSS13 deficient
mice yielded insights into a physiological role in epidermal barrier acquisition, however the
mechanism through which it mediates that effect remains unknown. Through biochemical
characterization, and investigations into a role of TMPRSS13 in breast cancer, thoughtful
insights into the functional role of TMPRSS13 in cancer progression have been elucidated.
Future studies in developing TMPRSS13 specific inhibitors, identification of TMPRSS13 specific
substrates, and identifying signaling pathways involved in TMPRSS13 phosphorylation will yield
fruitful answers to understanding the functional role of TMPRSS13 in both normal development
and disease.
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APPENDIX: SUPPLEMENTARY FIGURE
Supplementary Figure 21: Endogenous TMPRSS13 species
size and glycosylation status

Figure 21. (A) Lysates from HEK293T cells expressing WT-TMPRSS13 or S506A-TMPRSS13
were separated side-by-side with lysates from the indicated cell lines. Samples of lysates
expressing exogenous TMPRSS13 and lysates from samples containing endogenous
TMPRSS13 were separated by a ladder. (B) DLD1 cell lysates were treated with or without
PNGaseF and analyzed by Western blotting under reducing conditions using the α-intraTMPRSS13 antibody. The white arrowheads connected to black arrowheads indicate the
reduction in apparent molecular weight of the glycosylated forms of TMPRSS13.
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ABSTRACT
IDENTIFYING THE ROLE OF THE TYPE-II TRANSMEMBRANE SERINE PROTEASE
TMPRSS13 IN BREAST CANCER
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Breast cancer is the most frequently diagnosed cancer and the second leading cause of
cancer death in women in the United States. Breast cancer progression is accompanied by
increased expression of extracellular and cell surface proteases that are capable of degrading
the extracellular matrix as well as cleaving and activating downstream targets. These proteolytic
processes are critically involved in modifying the tissue microenvironment of the breast, which is
necessary for cancer cell invasion and eventual dissemination of cancer cells to other organs.
Therefore, identifying novel proteases that promote tumor progression is critical to create new
approaches for developing improved breast cancer therapeutics. Systematic in silico data
analysis followed by experimental validation identified increased expression of the type-II
transmembrane serine protease (TTSP) family member, TMPRSS13 (transmembrane protease,
serine 13), in invasive ductal carcinoma (IDC) patient tissue samples compared to normal
breast tissue. Immunohistochemical analysis revealed that the expression of TMPRSS13 is
strictly confined to the malignant epithelial cells and not the surrounding tumor stroma.
Currently, no studies have examined the role of TMPRSS13 in any cancer type. Additionally, the
basic biochemical properties (i.e. activation, localization, and post translational modifications)
have not yet been explored. Therefore to understand the potential role of TMPRSS13 in breast
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cancer, biochemical studies as well as thorough and comprehensive in vivo “loss-of-function”
studies complemented by human cell culture models were performed. Biochemical
characterization of TMPRSS13 show that TMPRSS13 is a glycosylated, active protease and
that its own proteolytic activity mediates zymogen cleavage. Full-length, active TMPRSS13
exhibits impaired cell-surface expression in the absence of the cognate Kunitz-type serine
protease inhibitors, hepatocyte growth factor activator inhibitor (HAI)-1 or HAI-2. Concomitant
presence of TMPRSS13 with either HAI-1 or -2 mediates phosphorylation of residues in the
intracellular domain of the protease, and it coincides with efficient transport of the protease to
the cell surface and its subsequent shedding. Cell-surface labeling experiments indicate that the
dominant form of TMPRSS13 on the cell surface is phosphorylated, whereas intracellular
TMPRSS13 is predominantly non-phosphorylated.
Additionally, results from the breast cancer study indicates that genetic deletion of
TMPRSS13 results in a significant decrease in overall tumor burden, growth rate, and a delayed
detection of palpable mammary tumors (tumor latency), thereby indicating that TMPRSS13
plays a promotional role in breast cancer progression. Complementary studies using human cell
culture models revealed that silencing TMPRSS13 expression decreases proliferation and
induces apoptosis. Furthermore, silencing of TMPRSS13 in the invasive human breast cancer
cell line BT20 attenuates its invasive potential. These studies are important to our
understanding of novel proteolytic events that occur within the tumor microenvironment, and in
determining whether TMPRSS13 may translate into a novel therapeutic target.

119

AUTOBIOGRAPHICAL STATEMENT
Andrew Stevan Murray
EDUCATION
Wayne State University Detroit, MI 2018
Doctor of Philosophy: Cancer Biology
Michigan State University East Lansing, MI 2011
Bachelor of Science: Microbiology & Human Biology
PUBLICATIONS
Murray AS, Varela FA, Hyland TE, Schoenbeck AJ, White JM, Tanabe LM, Todi SV, List
K. Phosphorylation of the type II transmembrane serine protease, TMPRSS13 in
Hepatocyte Growth Factor Activator Inhibitor-1 and 2-mediated cell surface
localization. J Biol Chem. 2017 Jul 14. pii: jbc.M117.775999. doi:
10.1074/jbc.M117.775999. [Epub ahead of print] PubMed PMID: 28710277.
Murray AS, Varela FA, List K. Type II transmembrane serine proteases as potential
targets for cancer therapy. Biol Chem. 2016 Sep 1;397(9):815-26. doi: 10.1515/hsz2016-0131. Review. PubMed PMID: 27078673
Duhaime MJ, Page KO, Varela FA, Murray AS, Silverman ME, Zoratti GL, List K. Cell
Surface Human Airway Trypsin-Like Protease Is Lost During Squamous Cell
Carcinogenesis. J Cell Physiol. 2016 Jul;231(7):1476-83. doi: 10.1002/jcp.25173. Epub
2016 Feb 4. PubMed PMID: 26297835
Zoratti GL, Tanabe LM, Varela FA, Murray AS, Bergum C, Colombo É, Lang JE,
Molinolo AA, Leduc R, Marsault E, Boerner J, List K. Targeting matriptase in breast
cancer abrogates tumour progression via impairment of stromal-epithelial growth factor
signalling. Nat Commun. 2015 Apr 15;6:6776. doi: 10.1038/ncomms7776. PubMed
PMID: 25873032
Miller GS, Zoratti GL, Murray AS, Bergum C, Tanabe LM, List K. HATL5: a cell surface
serine protease differentially expressed in epithelial cancers. PLoS One. 2014 Feb
3;9(2):e87675. doi: 10.1371/journal.pone.0087675. eCollection 2014. PubMed PMID:
24498351

